Aortic Valve Stenosis

Acquired MONDO:0042981 Pathograph 15 Show in embeddings browser

Progressive obstruction of left ventricular outflow caused by thickening, fibrosis, and calcification of the aortic valve leaflets. The dominant form in adults - calcific aortic valve disease - was long described as a passive "degenerative" wearing-out of the valve, but it is neither passive nor simply degenerative. It begins with an injury that looks like early atherosclerosis: endothelial disruption on the aortic side of the leaflet, subendothelial retention of apolipoprotein-B-containing lipoproteins, and a macrophage and T-cell infiltrate. It then becomes something atherosclerosis never becomes. Valve interstitial cells commit to an osteoblast-like transcriptional program - RUNX2/Cbfa1, osteopontin, osteocalcin, bone sialoprotein - and the leaflet actively mineralizes. That commitment is the pivot of the disease, and it explains the single most instructive negative result in the field: lipid lowering that demonstrably reduces ischemic events in the very same patients does nothing at all to the valve. Once the orifice narrows, the disease relocates. The valve sets the afterload, but survival is determined by what the left ventricle does about it - concentric hypertrophy, then diffuse interstitial and replacement myocardial fibrosis, then decompensation. Myocardial fibrosis burden, not valve gradient, tracks mortality. Valve replacement relieves the obstruction; it does not reverse established replacement fibrosis, which is why the timing question in asymptomatic severe stenosis remains genuinely unsettled rather than merely under-studied.

Ask OpenScientist

Ask a research question about Aortic Valve Stenosis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
10
Pathophys.
9
Phenotypes
3
Hypotheses
3
Gaps
15
Pathograph
2
Genes
3
Medical Actions
1
Deep Research
👪

Inheritance

1
◈

Mechanistic Hypotheses

3
Autonomous osteogenic program
osteogenic_autonomy CANONICAL
Evidence balance 1 support
Once valve interstitial cells commit to an osteoblast-like program, leaflet mineralization becomes an actively regulated, self-reinforcing process that no longer depends on continued lipoprotein exposure. Deposited mineral raises local leaflet stiffness and strain, which further promotes osteogenic commitment. The prediction is that interventions upstream of the commitment step - lipid lowering in particular - will fail to modify progression of established disease, which is what randomized trials found.
Pathograph links
Valve Interstitial Cell Osteogenic Transdifferentiation -> Valvular Calcification and Leaflet Mineralization DIRECT The osteoblast-like program deposits mineral within the leaflet.
Valvular Calcification and Leaflet Mineralization -> Valve Interstitial Cell Osteogenic Transdifferentiation INDIRECT KNOWN INTERMEDIATES Mineral deposition raises local leaflet stiffness and mechanical strain, which further promotes osteogenic commitment - the feed-forward loop that makes established disease self-sustaining.
Show evidence (1 reference)
PMID:12719282 SUPPORT Human Clinical
"aortic valve calcification is not a random degenerative process but an active regulated process associated with an osteoblast-like phenotype."
Supplies the core claim of an actively regulated osteogenic program in human calcified valves.
Lipid-driven atherosclerosis-like progression
lipid_driven_progression ⚠ DEPRECATED
⚠ Overturned model — shown for reference, not as current mechanism

DisMech records superseded hypotheses explicitly rather than deleting them, so that claims still circulating in reviews, textbooks and older diagnostic criteria can be checked against an assessment. This model is not part of the disease mechanism DisMech asserts.

Citation volume does not decide standing here. A hypothesis may retain more supporting than refuting citations simply because the supporting literature accumulated for decades before the refutation landed; where the two conflict, DisMech follows the more recent and more direct evidence. Supporting citations below are retained for the historical record.

Evidence balance 2 refute
The historical model held that calcific aortic stenosis is an atherosclerosis-like, lipid-driven process throughout its course, predicting that LDL lowering would slow or halt valve progression. Two randomized trials tested this directly and refuted it for established disease. The model is retained here rather than deleted because its failure is what motivates the osteogenic-autonomy account, and because it remains partially correct about initiation - the LPA genetic evidence shows a lipoprotein species is causal at the start.
Show evidence (2 references)
PMID:15944423 REFUTE Human Clinical
"Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression."
Directly refutes the prediction that lipid lowering modifies progression of established calcific aortic stenosis.
PMID:18765433 REFUTE Human Clinical
"Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-valve events and ischemic events in patients with aortic stenosis."
A second randomized trial refuting a lipid-lowering effect on aortic valve events.
Lipoprotein(a)-specific causal pathway
lipoprotein_a_specific_pathway EMERGING
Evidence balance 2 support
Lp(a), rather than LDL cholesterol generally, may be the lipoprotein species that matters for the valve - plausibly through the oxidized phospholipids it carries. This reconciles the causal genetic association at LPA with the failure of statin and ezetimibe therapy, neither of which meaningfully lowers Lp(a). The prediction is that selective Lp(a) lowering would slow valve disease where LDL lowering did not; this has not yet been tested against a valve endpoint, so the hypothesis is genuinely open rather than merely unfashionable.
Pathograph links
Lipoprotein(a) Burden -> Valve Endothelial Injury and Subendothelial Lipoprotein Retention INDIRECT KNOWN INTERMEDIATES Elevated circulating Lp(a) increases the pool of retainable lipoprotein bearing oxidized phospholipids available to the injured leaflet.
Lipoprotein(a) Burden -> Valvular Calcification and Leaflet Mineralization INDIRECT UNKNOWN INTERMEDIATES The genetic association is with valve calcification itself, an endpoint several steps downstream of retention; whether Lp(a) acts only through retention or also acts directly on the interstitial cell is unresolved.
Show evidence (2 references)
PMID:23388002 SUPPORT Human Clinical
"One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification"
Supplies the genome-wide genetic anchor that singles out the Lp(a) locus among lipid loci.
PMID:23388002 SUPPORT Human Clinical
"Currently, there are no treatments that prevent or slow the progression of valve disease."
Records the therapeutic vacuum this hypothesis proposes to fill, stated by the same authors who established the genetic association.
?

Discussions and Knowledge Gaps

3
Does myocardial fibrosis burden identify asymptomatic patients who benefit from early valve replacement, or is it only a marker of risk?
CONTROVERSY as_fibrosis_prognostic_vs_treatment_selection
Attached to
pathophysiology#Myocardial Interstitial and Replacement Fibrosis
The two questions are routinely conflated. Fibrosis burden is robustly prognostic - it predicts death and unplanned hospitalization in asymptomatic severe stenosis, and it grades mortality stepwise in symptomatic cohorts. It does not follow that intervening earlier in high-fibrosis patients helps. EVOLVED tested exactly this and found no interaction between fibrosis burden and treatment effect for the primary endpoint, although the hospitalization component did favor early intervention in the high-fibrosis group. A prognostic marker becomes a treatment-selection marker only when an interaction is demonstrated, and that demonstration has not been made.
Show evidence (2 references)
PMID:41984459 REFUTE Human Clinical
"There was no demonstrable heterogeneity by the degree of midwall fibrosis for the treatment effects of early surgical or transcatheter aortic valve replacement compared to clinical surveillance."
Directly refutes the treatment-selection interpretation of fibrosis burden on the trial's primary analysis.
PMID:41984459 SUPPORT Human Clinical
"unplanned aortic stenosis-related hospitalization in 4 (7%) and 13 (25%) patients respectively"
The component result that keeps the question open: hospitalizations differed substantially in the high-fibrosis group even though the primary endpoint showed no interaction.
Is the osteogenic commitment of valve interstitial cells reversible in vivo, and if so before what point?
KNOWLEDGE GAP as_osteogenic_commitment_reversibility
Attached to
pathophysiology#Valve Interstitial Cell Osteogenic Transdifferentiation
The whole therapeutic logic of this disease turns on this question. If commitment is a switch, the only useful window for medical therapy is before it is thrown, and every trial that enrolled established stenosis was destined to be negative for reasons unrelated to the drug. If it is a gradient sustained by ongoing signaling, established disease remains addressable. No human study has tested reversal of the osteogenic program, and the negative lipid-lowering trials cannot distinguish the two possibilities because they did not target the program itself.
Proposed experiments
Serial molecular imaging of valvular osteogenic activity during and after targeted intervention
exp_as_osteogenic_activity_reversal
Track valvular osteogenic activity by serial molecular imaging in patients receiving, then withdrawing, a targeted anti-osteogenic intervention. If activity falls with treatment and returns only slowly, commitment is signal-dependent and established disease is addressable; if activity is unchanged throughout, commitment is autonomous.
Randomized selective Lp(a) lowering with a valve-calcification endpoint in early disease
exp_as_lpa_lowering_valve_endpoint
Randomize patients with early calcific aortic valve disease to selective Lp(a) lowering versus placebo with progression of valve calcification as the primary endpoint. Intervening upstream of osteogenic commitment separates the initiation hypothesis from the autonomy hypothesis in a way the completed statin trials could not, because those enrolled established stenosis.
Should the valve interstitial cell have its own Cell Ontology term?
OPEN QUESTION as_valve_interstitial_cell_ontology_gap
Attached to
pathophysiology#Valve Interstitial Cell Osteogenic Transdifferentiation
The valve interstitial cell is the central effector cell of the commonest valve disease in the developed world, has a distinctive quiescent-to-activated-to-osteogenic phenotypic repertoire, and is not adequately represented by CL:0000057 (fibroblast), which is what this entry uses. The osteoblast-like state is likewise curated here as CL:0000062 (osteoblast), which asserts more lineage identity than the literature supports - the sources describe an acquired phenotype, not a lineage conversion. Both bindings are approximations recorded openly rather than silently.
⚙

Pathophysiology

10
Valve Endothelial Injury and Subendothelial Lipoprotein Retention
Mechanical and shear stress concentrated on the aortic side of the leaflet disrupts the valvular endothelium and its basement membrane, permitting apolipoprotein-B-containing lipoproteins - including lipoprotein(a) and its cargo of oxidized phospholipids - to enter and be retained in the subendothelial fibrosa. Retained lipid is oxidatively modified and becomes a standing pro-inflammatory stimulus. This is the initiating lesion of calcific aortic valve disease and is the stage at which the disease most resembles early atherosclerosis.
valvular endothelial cell CL:0000115 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves valvular endothelial cell, annotated with endothelial cell (CL:0000115). CL:0000115 is a cell type from the Cell Ontology.
response to fluid shear stress GO:0034405 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal response to fluid shear stress (GO:0034405). GO:0034405 is a biological process from the Gene Ontology. ⚠ ABNORMAL
aortic valve UBERON:0002137 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in aortic valve (UBERON:0002137). UBERON:0002137 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Chronic Valvular Inflammation Retained and oxidatively modified lipoprotein is the antigenic and pro-inflammatory stimulus that recruits the leukocyte infiltrate.
Show evidence (2 references)
PMID:7519131 SUPPORT Human Clinical
"Focal areas of thickening ("early lesions") were characterized by (1) subendothelial thickening on the aortic side of the leaflet, between the basement membrane"
Localizes the initiating lesion to the subendothelial space on the aortic side of the leaflet, the anatomic claim of this node.
PMID:7519131 SUPPORT Human Clinical
"extracellular neutral lipids (oil red O) and fine, stippled mineralization (von Kossa), and (3) disruption of the basement membrane overlying the lesion."
Documents retained extracellular lipid together with basement-membrane disruption in the early lesion, the lipoprotein-retention claim.
Lipoprotein(a) Burden
Genetically determined circulating lipoprotein(a) concentration is a causal driver of aortic valve calcification and of incident clinical aortic stenosis. The LPA locus is the only variant to reach genome-wide significance for aortic valve calcification, the association replicates across white European, African-American, and Hispanic-American cohorts, and genetically predicted Lp(a) levels - which are not confounded by reverse causation - carry the same association. This is the strongest evidence that a lipoprotein species is causal in this disease, and it stands in deliberate tension with the failure of LDL lowering to modify valve progression.
Lipoprotein(a)-specific causal pathway
LPA hgnc:6667 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves LPA (hgnc:6667). hgnc:6667 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Valve Endothelial Injury and Subendothelial Lipoprotein Retention Elevated circulating Lp(a) increases the pool of retainable lipoprotein bearing oxidized phospholipids available to the injured leaflet. Lipoprotein(a)-specific causal pathway
Valvular Calcification and Leaflet Mineralization The genetic association is with valve calcification itself, an endpoint several steps downstream of retention; whether Lp(a) acts only through retention or also acts directly on the interstitial cell is unresolved. Lipoprotein(a)-specific causal pathway
Show evidence (2 references)
PMID:23388002 SUPPORT Human Clinical
"Genetic variation in the LPA locus, mediated by Lp(a) levels, is associated with aortic-valve calcification across multiple ethnic groups and with incident clinical aortic stenosis."
Establishes an Lp(a)-mediated genetic contribution to both valve calcification and incident clinical stenosis.
PMID:23388002 SUPPORT Human Clinical
"Genetically determined Lp(a) levels, as predicted by LPA genotype, were also associated with aortic-valve calcification, supporting a causal role for Lp(a)."
Supplies the causal-inference step: genotype-predicted Lp(a) carries the association, which is what distinguishes causation from confounded correlation here.
Chronic Valvular Inflammation
The early lesion is not acellular debris. It contains an active inflammatory infiltrate of non-foam-cell and foam-cell macrophages with occasional T lymphocytes, absent from normal leaflets. Chronic inflammation sustains oxidative modification of retained lipid and supplies the cytokine environment in which resident interstitial cells adopt an osteogenic program.
valvular foam-cell macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves valvular foam-cell macrophage, annotated with macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology. infiltrating T lymphocyte CL:0000084 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves infiltrating T lymphocyte, annotated with T cell (CL:0000084). CL:0000084 is a cell type from the Cell Ontology.
inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Valve Interstitial Cell Osteogenic Transdifferentiation Inflammatory and oxidative signaling in the fibrosa drives resident interstitial cells toward an osteoblast-like phenotype.
Show evidence (2 references)
PMID:7519131 SUPPORT Human Clinical
"early lesions were characterized by the presence of an inflammatory infiltrate composed of non-foam cell and foam cell macrophages, occasional T cells, and rare alpha-actin-positive cells."
Directly characterizes the cellular composition asserted by this node.
PMID:7519131 SUPPORT Human Clinical
"The early lesion of "degenerative" aortic stenosis is an active inflammatory process"
States the central reframing this node encodes - an active inflammatory process rather than passive degeneration.
Bicuspid Aortic Valve Morphology
A two-leaflet rather than three-leaflet aortic valve is present in 1-2% of the population and imposes abnormal leaflet stress and turbulent transvalvular flow from birth. It is the commonest congenital substrate for calcific stenosis and shifts presentation decades earlier. NOTCH1 loss-of-function links the two halves of the phenotype mechanistically: it produces the developmental leaflet anomaly, and because NOTCH1 signaling represses RUNX2, it also de-represses the osteogenic program that later calcifies the valve. The same lesion therefore both malforms the valve and removes a brake on its mineralization.
NOTCH1 hgnc:7881 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves NOTCH1 (hgnc:7881). hgnc:7881 is a gene from the HUGO Gene Nomenclature Committee.
aortic valve UBERON:0002137 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in aortic valve (UBERON:0002137). UBERON:0002137 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Valve Endothelial Injury and Subendothelial Lipoprotein Retention Abnormal leaflet geometry concentrates mechanical and shear stress, accelerating endothelial injury.
Valve Interstitial Cell Osteogenic Transdifferentiation NOTCH1 haploinsufficiency de-represses RUNX2, lowering the threshold for osteogenic commitment independently of the flow abnormality.
Show evidence (2 references)
PMID:16025100 SUPPORT Human Clinical
"we show that mutations in the signalling and transcriptional regulator NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe valve calcification in non-syndromic autosomal-dominant human pedigrees."
Establishes NOTCH1 as causal for both the developmental valve anomaly and the later severe calcification in human pedigrees.
PMID:16025100 SUPPORT Human Clinical
"The incidence increases with age, and it is often associated with a bicuspid aortic valve present in 1-2% of the population."
Supports the population frequency of the bicuspid substrate stated here.
Valve Interstitial Cell Osteogenic Transdifferentiation
The pivot of the disease. Resident valve interstitial cells - fibroblast-like cells of the leaflet - switch to an osteoblast-like transcriptional program. Calcified human valves show increased expression of osteopontin, bone sialoprotein, osteocalcin, and the osteoblast master transcription factor RUNX2/Cbfa1 relative to normal valves. This is the step that separates calcific aortic valve disease from atherosclerosis: the tissue does not merely accumulate lipid and mineral debris, it executes a bone-formation program. NOTCH1 signaling normally represses RUNX2, which is why NOTCH1 loss both malforms and calcifies the valve.
Autonomous osteogenic program
valve interstitial cell CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves valve interstitial cell, annotated with fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology. osteoblast-like valve interstitial cell CL:0000062 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves osteoblast-like valve interstitial cell, annotated with osteoblast (CL:0000062). CL:0000062 is a cell type from the Cell Ontology.
RUNX2 hgnc:10472 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves RUNX2 (hgnc:10472). hgnc:10472 is a gene from the HUGO Gene Nomenclature Committee.
osteoblast differentiation GO:0001649 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased osteoblast differentiation (GO:0001649). GO:0001649 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Valvular Calcification and Leaflet Mineralization The osteoblast-like program deposits mineral within the leaflet. Autonomous osteogenic program
Show evidence (3 references)
PMID:12719282 SUPPORT Human Clinical
"Reverse transcriptase-polymerase chain reaction revealed increased mRNA levels of osteopontin, bone sialoprotein, osteocalcin, and Cbfa1 in the calcified valves."
Provides the direct molecular evidence for an osteoblast transcriptional program in human calcified valves compared with normal valves.
PMID:12719282 SUPPORT Human Clinical
"These findings support the concept that aortic valve calcification is not a random degenerative process but an active regulated process associated with an osteoblast-like phenotype."
States the reframing this node encodes - an actively regulated osteogenic process rather than passive degeneration.
PMID:16025100 SUPPORT In Vitro
"Notch1 repressed the activity of Runx2, a central transcriptional regulator of osteoblast cell fate."
Supplies the molecular mechanism linking NOTCH1 loss to de-repression of the osteogenic program. Evidence source is IN_VITRO because the repression was demonstrated in cell-based transcriptional assays.
Valvular Calcification and Leaflet Mineralization
Calcium-phosphate mineral is laid down within the leaflet with the ultrastructure and composition of bone - hydroxyapatite, elemental calcium phosphate on energy-dispersive spectroscopy, mineralization borders on von Kossa staining. Mineralization stiffens the leaflet and further increases local mechanical stress, so the lesion is self-reinforcing. The extent of valvular calcification, not the patient's age, sex, or coronary or metabolic risk factors, is the independent predictor of clinical outcome in asymptomatic disease.
Autonomous osteogenic program
bone mineralization GO:0030282 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased bone mineralization (GO:0030282). GO:0030282 is a biological process from the Gene Ontology. ↑ INCREASED extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ⚠ ABNORMAL
aortic valve UBERON:0002137 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in aortic valve (UBERON:0002137). UBERON:0002137 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Progressive Left Ventricular Outflow Obstruction Leaflet stiffening restricts systolic excursion and narrows the effective orifice area.
Valve Interstitial Cell Osteogenic Transdifferentiation Mineral deposition raises local leaflet stiffness and mechanical strain, which further promotes osteogenic commitment - the feed-forward loop that makes established disease self-sustaining. Autonomous osteogenic program
Show evidence (2 references)
PMID:12719282 SUPPORT Human Clinical
"Special stains for hydroxyapatite and CaPO4 were positive in calcification margins. Electron microscopy identified mineralization, whereas energy-dispersive spectroscopy confirmed the presence of elemental CaPO4."
Confirms that the deposited mineral is bone-type calcium phosphate rather than nonspecific debris.
PMID:10965007 SUPPORT Human Clinical
"According to multivariate analysis, only the extent of aortic-valve calcification was an independent predictor of outcome, whereas age, sex, and the presence or absence of coronary artery disease, hypertension, diabetes, and hypercholesterolemia were not."
Establishes leaflet calcification as the independent outcome determinant, and by exclusion shows that atherosclerotic risk factors are not.
Progressive Left Ventricular Outflow Obstruction
The stiffened, mineralized valve narrows the outflow orifice, raising transvalvular velocity and the systolic pressure gradient the ventricle must generate. Progression is not uniform: the rate of increase in aortic-jet velocity varies widely between patients and is itself prognostic, separating those who will have events within a year or two from those who will not. This is why the disease is staged by progression rate as well as by severity.
aortic valve UBERON:0002137 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in aortic valve (UBERON:0002137). UBERON:0002137 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Left Ventricular Pressure Overload and Concentric Hypertrophy A sustained systolic pressure gradient is the afterload stimulus for hypertrophic remodeling.
Show evidence (1 reference)
PMID:10965007 SUPPORT Human Clinical
"The rate of progression of stenosis, as reflected by the aortic-jet velocity, was significantly higher in patients who had cardiac events"
Supports both progressive obstruction and the prognostic weight of its rate rather than its instantaneous severity.
Left Ventricular Pressure Overload and Concentric Hypertrophy
The ventricle compensates for the fixed outflow obstruction by concentric hypertrophy, normalizing wall stress at the cost of a thicker, stiffer, less compliant chamber with a higher oxygen demand and a compressed subendocardial perfusion reserve. Hypertrophy is adaptive in the short term and the substrate for decompensation in the long term. Angina in aortic stenosis frequently occurs with unobstructed epicardial coronary arteries, reflecting this supply-demand mismatch rather than coexisting coronary disease.
cardiomyocyte CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cardiomyocyte, annotated with cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
heart left ventricle UBERON:0002084 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart left ventricle (UBERON:0002084). UBERON:0002084 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Myocardial Interstitial and Replacement Fibrosis Sustained pressure overload and the resulting myocardial injury drive expansion of the extracellular compartment and focal replacement fibrosis.
Show evidence (1 reference)
PMID:28017384 SUPPORT Human Clinical
"Progressive myocardial fibrosis drives the transition from hypertrophy to heart failure in aortic stenosis."
Places hypertrophy as the compensated stage preceding the fibrotic transition modeled downstream.
Myocardial Interstitial and Replacement Fibrosis
Pressure-overloaded myocardium accumulates two distinguishable kinds of fibrosis. Diffuse interstitial fibrosis expands the myocardial extracellular volume and is at least partly reversible after the load is relieved. Replacement fibrosis - focal midwall scar following cardiomyocyte death, detected as late gadolinium enhancement - is not. Patients sort into a stepwise mortality gradient across normal myocardium, extracellular expansion, and replacement fibrosis, and in asymptomatic severe stenosis midwall fibrosis burden carries measurable additional risk. This is the node at which the disease stops being about the valve.
cardiac fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cardiac fibroblast, annotated with fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
extracellular matrix organization GO:0030198 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased extracellular matrix organization (GO:0030198). GO:0030198 is a biological process from the Gene Ontology. ↑ INCREASED
heart left ventricle UBERON:0002084 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart left ventricle (UBERON:0002084). UBERON:0002084 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Left Ventricular Decompensation and Symptom Onset Fibrosis produces the diastolic and longitudinal systolic dysfunction that manifests as symptoms and drives events.
Show evidence (4 references)
PMID:28017384 SUPPORT Human Clinical
"Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis."
Establishes the two-compartment distinction between diffuse interstitial and focal replacement fibrosis that this node asserts.
PMID:28017384 SUPPORT Human Clinical
"this categorization was of prognostic value with stepwise increases in unadjusted all-cause mortality"
Supports the stepwise mortality gradient across normal myocardium, extracellular expansion, and replacement fibrosis.
PMID:28017384 SUPPORT Human Clinical
"iECV demonstrated a good correlation with diffuse histological fibrosis on myocardial biopsies"
Validates the imaging surrogate against histology, which is what licenses treating extracellular volume as a fibrosis measurement rather than an imaging artifact.
+ 1 more reference
Left Ventricular Decompensation and Symptom Onset
Diastolic dysfunction, longitudinal systolic dysfunction, and myocardial injury accumulate across the fibrosis stages until the compensated ventricle fails, producing exertional dyspnea, angina, syncope, and ultimately heart failure. Symptom onset is the classical trigger for intervention, and in prospectively followed asymptomatic patients almost all cardiac deaths were preceded by symptoms - which is what makes watchful waiting defensible, and also what makes the residual sudden-death risk so difficult to quantify.
heart left ventricle UBERON:0002084 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in heart left ventricle (UBERON:0002084). UBERON:0002084 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:28017384 SUPPORT Human Clinical
"There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction, and longitudinal systolic dysfunction consistent with progressive left ventricular decompensation"
Documents the physiological components of decompensation tracking with fibrosis stage.
PMID:10965007 SUPPORT Human Clinical
"Five of the six deaths from cardiac disease were preceded by symptoms."
Supports symptom onset as the near-universal antecedent of cardiac death in this cohort, the observation on which watchful waiting rests.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Aortic Valve Stenosis Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Cardiovascular 6
Aortic Valve Stenosis HP:0001650 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic valve stenosis (HP:0001650), qualified as course progressive. HP:0001650 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:10965007 SUPPORT Human Clinical
"we identified 128 consecutive patients with asymptomatic, severe aortic stenosis"
Identifies the defining lesion in a prospectively assembled clinical cohort.
Bicuspid Aortic Valve HP:0001647 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bicuspid aortic valve (HP:0001647). HP:0001647 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:16025100 SUPPORT Human Clinical
"it is often associated with a bicuspid aortic valve present in 1-2% of the population."
Supports the association of valve calcification with a bicuspid valve and its population frequency.
Left Ventricular Hypertrophy HP:0001712 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Left ventricular hypertrophy (HP:0001712). HP:0001712 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28017384 SUPPORT Human Clinical
"There was evidence of increasing hypertrophy, myocardial injury, diastolic dysfunction, and longitudinal systolic dysfunction"
Documents hypertrophy in a phenotyped aortic stenosis cohort.
Angina Pectoris HP:0001681 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Angina pectoris (HP:0001681). HP:0001681 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:24104373 SUPPORT Human Clinical
"Angina, exertional syncope, and heart failure are key symptoms indicating a need for intervention."
Names angina among the symptoms whose appearance indicates a need for intervention.
PMID:12732812 SUPPORT Human Clinical
"Eventually, symptoms of angina, non-Q wave myocardial infarction, exertional syncope, and heart failure occur."
Independent source placing angina in the natural history of valvular aortic stenosis, alongside non-Q-wave infarction - which supports the supply-demand rather than epicardial-obstruction reading curated in the description.
Syncope HP:0001279 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Syncope (HP:0001279). HP:0001279 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:24104373 SUPPORT Human Clinical
"Angina, exertional syncope, and heart failure are key symptoms indicating a need for intervention."
Names syncope, and specifically its exertional character, among the intervention-triggering symptoms.
PMID:12732812 SUPPORT Human Clinical
"Eventually, symptoms of angina, non-Q wave myocardial infarction, exertional syncope, and heart failure occur."
Independent source placing exertional syncope in the natural history of valvular aortic stenosis.
Congestive Heart Failure HP:0001635 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Congestive heart failure (HP:0001635). HP:0001635 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28017384 SUPPORT Human Clinical
"Progressive myocardial fibrosis drives the transition from hypertrophy to heart failure in aortic stenosis."
Supports heart failure as the terminal ventricular phenotype of the disease.
Other 3
Aortic Valve Calcification HP:0004380 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Aortic valve calcification (HP:0004380). HP:0004380 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12719282 SUPPORT Human Clinical
"Microradiography and micro-computerized tomography confirmed the presence of calcification in the valve."
Directly documents leaflet calcification in surgically explanted human valves.
Myocardial Fibrosis HP:0001685 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myocardial fibrosis (HP:0001685), qualified as course progressive. HP:0001685 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:28017384 SUPPORT Human Clinical
"iECV demonstrated a good correlation with diffuse histological fibrosis on myocardial biopsies"
Anchors the fibrosis phenotype on histologically validated measurement.
Exertional Dyspnea HP:0002875 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Exertional dyspnea (HP:0002875). HP:0002875 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24104373 SUPPORT Human Clinical
"Angina, exertional syncope, and heart failure are key symptoms indicating a need for intervention."
Names the symptom set that triggers intervention. Dyspnea is curated here as the presenting manifestation of the heart-failure component of that set.
🧬

Genetic Associations

2
LPA
Gene: LPA hgnc:6667 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is LPA (hgnc:6667). hgnc:6667 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (1 reference)
PMID:23388002 SUPPORT Human Clinical
"One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide significance for the presence of aortic-valve calcification"
Genome-wide significant association of the LPA locus with aortic valve calcification.
NOTCH1
Gene: NOTCH1 hgnc:7881 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NOTCH1 (hgnc:7881). hgnc:7881 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:16025100 SUPPORT Human Clinical
"mutations in the signalling and transcriptional regulator NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe valve calcification in non-syndromic autosomal-dominant human pedigrees."
Establishes NOTCH1 as a causal gene for human aortic valve disease.
💊

Medical Actions

3
Surgical Aortic Valve Replacement
Action: aortic valve replacementNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is aortic valve replacement (NCIT:C50815). NCIT:C50815 is a clinical intervention from the NCI Thesaurus. Ontology label: Aortic Valve Replacement NCIT:C50815
Open surgical excision of the diseased valve and implantation of a mechanical or bioprosthetic replacement. Relieves the outflow obstruction and permits regression of hypertrophy and of diffuse interstitial fibrosis, but does not reverse established replacement fibrosis.
Mechanism Target:
INHIBITS Progressive Left Ventricular Outflow Obstruction — Replacing the leaflets eliminates the fixed obstruction and the pressure gradient driving ventricular remodeling.
Show evidence (1 reference)
PMID:10965007 SUPPORT Human Clinical
"These patients should be considered for early valve replacement rather than have surgery delayed until symptoms develop."
Supports valve replacement as the definitive intervention and identifies the high-risk subgroup in whom earlier operation was recommended.
Transcatheter Aortic Valve Replacement
Action: transcatheter aortic valve replacementNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is transcatheter aortic valve replacement (NCIT:C158018). NCIT:C158018 is a clinical intervention from the NCI Thesaurus. Ontology label: Transcatheter Aortic Valve Replacement NCIT:C158018
Catheter-delivered implantation of a bioprosthetic valve within the diseased native valve, avoiding sternotomy and cardiopulmonary bypass. Now used across the surgical risk spectrum.
Mechanism Target:
INHIBITS Progressive Left Ventricular Outflow Obstruction — The implanted prosthesis displaces the calcified native leaflets and restores an unobstructed outflow orifice.
Show evidence (1 reference)
PMID:41984459 SUPPORT Human Clinical
"Early intervention with transcatheter or surgical aortic valve replacement."
Identifies transcatheter replacement alongside surgery as the intervention randomized in contemporary trials.
Lipid-Lowering Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Statin and ezetimibe therapy, historically expected to slow valve progression on the atherosclerosis analogy. Randomized trials refute this for the valve. Recorded here because the negative result is mechanistically informative rather than merely absent: in SEAS the same intervention in the same patients reduced ischemic events while leaving valve events untouched, dissociating the arterial from the valvular disease.
Mechanism Target:
INHIBITS Valve Endothelial Injury and Subendothelial Lipoprotein Retention — Intended to reduce the retainable apoB-lipoprotein pool at the initiating lesion. The intended effect on valve progression was not observed.
Show evidence (4 references)
PMID:15944423 REFUTE Human Clinical
"Intensive lipid-lowering therapy does not halt the progression of calcific aortic stenosis or induce its regression."
Refutes a disease-modifying effect of lipid lowering on the valve lesion.
PMID:18765433 REFUTE Human Clinical
"Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-valve events and ischemic events in patients with aortic stenosis."
Second randomized refutation, on the primary composite endpoint.
PMID:18765433 REFUTE Human Clinical
"Aortic-valve replacement was performed in 267 patients (28.3%) in the simvastatin-ezetimibe group and in 278 patients (29.9%) in the placebo group (hazard ratio, 1.00; 95%"
The valve-specific null quantified: a hazard ratio of exactly 1.00 for aortic-valve replacement.
+ 1 more reference
🔬

Diagnosis

3
Transthoracic Echocardiography
The diagnostic and staging modality. Echocardiography establishes leaflet calcification and restriction and quantifies severity by transvalvular peak velocity, mean gradient, and effective orifice area. It is also what defines disease progression in this entry, since the prognostic rate-of-change data are expressed as change in aortic-jet velocity per year.
echocardiography NCIT:C16525 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:10965007 SUPPORT Human Clinical
"The rate of progression of stenosis, as reflected by the aortic-jet velocity, was significantly higher in patients who had cardiac events"
Documents the echocardiographic measurement (aortic-jet velocity) used to stage severity and track progression, and its prognostic weight.
Exercise Stress Testing
Used to unmask symptoms in patients who report none, which matters because the whole management algorithm pivots on symptom status and patients routinely under-report by limiting their own activity. In the EARLY TAVR screening cohort, standardized treadmill testing of apparently asymptomatic patients with severe stenosis was positive in 15.2% - meaning roughly one in seven "asymptomatic" patients was not. It is safe in this population and nonetheless infrequently used.
exercise cardiac stress test NCIT:C168192 NCI Thesaurus (NCIT)
Show evidence (3 references)
PMID:42485012 SUPPORT Human Clinical
"In patients with asymptomatic severe aortic stenosis (AS), exercise stress testing is recommended to unmask symptoms and guide the timing of intervention, yet it is infrequently used in clinical practice."
States both the indication and the practice gap this entry records.
PMID:42485012 SUPPORT Human Clinical
"Of these, 816 (84.8%) had a normal TST result and 146 (15.2%) had a positive TST result."
Quantifies how often apparently asymptomatic severe stenosis is unmasked by testing, which is what makes symptom status a measured rather than a reported variable.
PMID:42485012 SUPPORT Human Clinical
"TST was found to be safe, with no reported deaths, syncope, or cardioversions."
Addresses the historical safety concern about exercising patients with severe outflow obstruction.
Cardiac Magnetic Resonance with Late Gadolinium Enhancement
Not needed to diagnose the valve lesion, but the only way to see the ventricular disease that determines survival. T1 mapping quantifies extracellular volume expansion (diffuse interstitial fibrosis) and late gadolinium enhancement detects focal replacement fibrosis; the two together stratify mortality stepwise, and midwall fibrosis burden is prognostic even in patients whose valve does not yet meet intervention criteria.
cardiac magnetic resonance imaging NCIT:C16809 NCI Thesaurus (NCIT)
Show evidence (2 references)
PMID:28017384 SUPPORT Human Clinical
"Diffuse fibrosis is associated with extracellular volume expansion that is detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects replacement fibrosis."
Establishes the two cardiac magnetic resonance measurements and what each detects.
PMID:28017384 SUPPORT Human Clinical
"CMR detects ventricular decompensation in aortic stenosis through the identification of myocardial extracellular expansion and replacement fibrosis."
States the diagnostic claim: cardiac magnetic resonance is how ventricular decompensation is detected in this disease.
📊

Prevalence

1
Worldwide (Global Burden of Disease estimates)
Point Prevalence 138.0 per 100,000 (120.0–158.0) >1 in 1,000
9.6-12.6 million people worldwide with calcific aortic valve stenosis per Global Burden of Disease estimates. The rates per 100,000 are derived from those counts against a world population of roughly 8 billion and are therefore approximate; the count, not the rate, is what the source states.
Show evidence (1 reference)
PMID:42177117 SUPPORT Other
"The worldwide prevalence of CAVS is rising, affecting a 9.6 to 12.6 million people according to Global Disease Burden estimates"
Supplies the worldwide case count. Evidence source is OTHER because this is a narrative review of Global Burden of Disease estimates.
🌍

Epidemiology

3
Global mortality burden
Calcific aortic valve stenosis contributes over 100,000 deaths worldwide each year, and the source attaches that burden specifically to the post-symptomatic phase - which is the entry's organising point restated epidemiologically.
Show evidence (1 reference)
PMID:42177117 SUPPORT Other
"Once symptoms emerge, CAVS is associated with high morbidity and mortality, contributing to over 100,000 deaths globally each year."
Quantifies annual mortality and ties it to symptom emergence rather than to the presence of the valve lesion. Evidence source is OTHER because this is a narrative review.
Rising global burden
Prevalence and incidence rose globally between 1990 and 2021, with the highest burdens in Western Europe and North America; ageing and population growth are the principal drivers.
Show evidence (2 references)
PMID:42129826 SUPPORT Human Clinical
"The prevalence and incidence of NRCAVD increased globally between 1990 and 2021, with higher burdens in Western Europe and North America."
Documents the direction and geography of the trend from Global Burden of Disease data.
PMID:42129826 SUPPORT Human Clinical
"Aging and population growth drove the increase in DALYs, while body mass index was identified as a causal risk factor."
Attributes the rising burden to demography and identifies body mass index as causal by Mendelian randomization.
Event-free survival in asymptomatic severe aortic stenosis
Event-free survival in prospectively followed asymptomatic severe stenosis falls steeply, and the extent of valvular calcification stratifies it sharply.
Show evidence (1 reference)
PMID:10965007 SUPPORT Human Clinical
"Event-free survival for patients with no or mild valvular calcification was 92+/-5 percent at one year"
Quantifies outcome in the low-calcification stratum of a prospective asymptomatic cohort.
{ }

Source YAML

click to show 
name: Aortic Valve Stenosis
creation_date: "2026-08-10T13:40:00Z"
category: Acquired
disease_term:
  preferred_term: aortic valve stenosis
  term:
    id: MONDO:0042981
    label: aortic valve stenosis
description: >
  Progressive obstruction of left ventricular outflow caused by thickening,
  fibrosis, and calcification of the aortic valve leaflets. The dominant form in
  adults - calcific aortic valve disease - was long described as a passive
  "degenerative" wearing-out of the valve, but it is neither passive nor simply
  degenerative. It begins with an injury that looks like early atherosclerosis:
  endothelial disruption on the aortic side of the leaflet, subendothelial
  retention of apolipoprotein-B-containing lipoproteins, and a macrophage and
  T-cell infiltrate. It then becomes something atherosclerosis never becomes.
  Valve interstitial cells commit to an osteoblast-like transcriptional program -
  RUNX2/Cbfa1, osteopontin, osteocalcin, bone sialoprotein - and the leaflet
  actively mineralizes. That commitment is the pivot of the disease, and it
  explains the single most instructive negative result in the field: lipid
  lowering that demonstrably reduces ischemic events in the very same patients
  does nothing at all to the valve.
  Once the orifice narrows, the disease relocates. The valve sets the afterload,
  but survival is determined by what the left ventricle does about it -
  concentric hypertrophy, then diffuse interstitial and replacement myocardial
  fibrosis, then decompensation. Myocardial fibrosis burden, not valve gradient,
  tracks mortality. Valve replacement relieves the obstruction; it does not
  reverse established replacement fibrosis, which is why the timing question in
  asymptomatic severe stenosis remains genuinely unsettled rather than merely
  under-studied.
synonyms:
- calcific aortic valve disease
- calcific aortic stenosis
- aortic stenosis
notes: >
  Deliberate non-conformance to the `atherogenesis` module. The temptation is
  strong: the early valve lesion carries retained lipid, oxidized lipoprotein,
  foam-cell macrophages, and T cells (PMID:7519131), and the strongest common
  genetic signal is at LPA, a lipoprotein locus (PMID:23388002). But the
  module's own curation boundary requires "retention of apoB-containing
  lipoprotein in the arterial intima" and explicitly excludes "foam cells outside
  arterial atheroma" and "nonatherosclerotic stenosis". The aortic valve
  fibrosa is not arterial intima, the terminal lesion is a mineralized leaflet
  rather than an atheroma at UBERON:0001637 artery, and no conforming node here
  would reach the module's required smooth-muscle-cell fibrofatty-plaque stage.
  Declaring conformance at the initiation node alone would assert an arterial
  site the disorder does not have.
  The negative trial evidence makes the same point from the therapeutic side and
  is the reason this decision is recorded rather than assumed. Otto's own
  conclusion in the founding histology paper was that the early lesion has "some
  similarities ... and some dissimilarities to atherosclerosis" - a claim of
  partial resemblance, which is exactly what a module conformance is not.

  No CL term exists for the valve interstitial cell, the central effector cell of
  this disease. CL:0000057 (fibroblast) is used with a specific `preferred_term`
  throughout; the osteogenic end state is represented separately by CL:0000062
  (osteoblast), which the literature describes as a phenotype the interstitial
  cell acquires rather than a distinct lineage. This is an ontology gap, not a
  curation shortcut.

  Ross and Braunwald's 1968 natural-history study - the source of the classic
  angina/syncope/heart-failure survival figures - has no abstract in PubMed and
  therefore cannot be quoted under this project's evidence rules. The symptom
  and outcome claims here are anchored on PMID:10965007 instead, which reports
  prospectively collected event-free survival.
pathophysiology:
- name: Valve Endothelial Injury and Subendothelial Lipoprotein Retention
  biological_scale: TISSUE
  role: trigger
  description: >
    Mechanical and shear stress concentrated on the aortic side of the leaflet
    disrupts the valvular endothelium and its basement membrane, permitting
    apolipoprotein-B-containing lipoproteins - including lipoprotein(a) and its
    cargo of oxidized phospholipids - to enter and be retained in the
    subendothelial fibrosa. Retained lipid is oxidatively modified and becomes a
    standing pro-inflammatory stimulus. This is the initiating lesion of calcific
    aortic valve disease and is the stage at which the disease most resembles
    early atherosclerosis.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  cell_types:
  - preferred_term: valvular endothelial cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: response to fluid shear stress
    term:
      id: GO:0034405
      label: response to fluid shear stress
    modifier: ABNORMAL
  evidence:
  - reference: PMID:7519131
    reference_title: "Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Focal areas of thickening ("early lesions") were characterized by (1)
      subendothelial thickening on the aortic side of the leaflet, between the
      basement membrane
    explanation: >-
      Localizes the initiating lesion to the subendothelial space on the aortic
      side of the leaflet, the anatomic claim of this node.
  - reference: PMID:7519131
    reference_title: "Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      extracellular neutral lipids (oil red O) and fine, stippled mineralization
      (von Kossa), and (3) disruption of the basement membrane overlying the
      lesion.
    explanation: >-
      Documents retained extracellular lipid together with basement-membrane
      disruption in the early lesion, the lipoprotein-retention claim.
  downstream:
  - target: Chronic Valvular Inflammation
    causal_link_type: DIRECT
    description: >-
      Retained and oxidatively modified lipoprotein is the antigenic and
      pro-inflammatory stimulus that recruits the leukocyte infiltrate.
- name: Lipoprotein(a) Burden
  biological_scale: ORGANISM
  role: trigger
  description: >
    Genetically determined circulating lipoprotein(a) concentration is a causal
    driver of aortic valve calcification and of incident clinical aortic
    stenosis. The LPA locus is the only variant to reach genome-wide significance
    for aortic valve calcification, the association replicates across white
    European, African-American, and Hispanic-American cohorts, and genetically
    predicted Lp(a) levels - which are not confounded by reverse causation -
    carry the same association. This is the strongest evidence that a lipoprotein
    species is causal in this disease, and it stands in deliberate tension with
    the failure of LDL lowering to modify valve progression.
  genes:
  - preferred_term: LPA
    term:
      id: hgnc:6667
      label: LPA
  evidence:
  - reference: PMID:23388002
    reference_title: "Genetic associations with valvular calcification and aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic variation in the LPA locus, mediated by Lp(a) levels, is associated
      with aortic-valve calcification across multiple ethnic groups and with
      incident clinical aortic stenosis.
    explanation: >-
      Establishes an Lp(a)-mediated genetic contribution to both valve
      calcification and incident clinical stenosis.
  - reference: PMID:23388002
    reference_title: "Genetic associations with valvular calcification and aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetically determined Lp(a) levels, as predicted by LPA genotype, were
      also associated with aortic-valve calcification, supporting a causal role
      for Lp(a).
    explanation: >-
      Supplies the causal-inference step: genotype-predicted Lp(a) carries the
      association, which is what distinguishes causation from confounded
      correlation here.
  downstream:
  - target: Valve Endothelial Injury and Subendothelial Lipoprotein Retention
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Elevated circulating Lp(a) increases the pool of retainable lipoprotein
      bearing oxidized phospholipids available to the injured leaflet.
    hypothesis_groups:
    - lipoprotein_a_specific_pathway
  - target: Valvular Calcification and Leaflet Mineralization
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The genetic association is with valve calcification itself, an endpoint
      several steps downstream of retention; whether Lp(a) acts only through
      retention or also acts directly on the interstitial cell is unresolved.
    hypothesis_groups:
    - lipoprotein_a_specific_pathway
- name: Chronic Valvular Inflammation
  biological_scale: CELLULAR
  description: >
    The early lesion is not acellular debris. It contains an active inflammatory
    infiltrate of non-foam-cell and foam-cell macrophages with occasional T
    lymphocytes, absent from normal leaflets. Chronic inflammation sustains
    oxidative modification of retained lipid and supplies the cytokine
    environment in which resident interstitial cells adopt an osteogenic program.
  cell_types:
  - preferred_term: valvular foam-cell macrophage
    term:
      id: CL:0000235
      label: macrophage
  - preferred_term: infiltrating T lymphocyte
    term:
      id: CL:0000084
      label: T cell
  biological_processes:
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
    modifier: INCREASED
  evidence:
  - reference: PMID:7519131
    reference_title: "Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      early lesions were characterized by the presence of an inflammatory
      infiltrate composed of non-foam cell and foam cell macrophages, occasional
      T cells, and rare alpha-actin-positive cells.
    explanation: >-
      Directly characterizes the cellular composition asserted by this node.
  - reference: PMID:7519131
    reference_title: "Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The early lesion of "degenerative" aortic stenosis is an active
      inflammatory process
    explanation: >-
      States the central reframing this node encodes - an active inflammatory
      process rather than passive degeneration.
  downstream:
  - target: Valve Interstitial Cell Osteogenic Transdifferentiation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Inflammatory and oxidative signaling in the fibrosa drives resident
      interstitial cells toward an osteoblast-like phenotype.
- name: Bicuspid Aortic Valve Morphology
  biological_scale: TISSUE
  role: trigger
  description: >
    A two-leaflet rather than three-leaflet aortic valve is present in 1-2% of
    the population and imposes abnormal leaflet stress and turbulent
    transvalvular flow from birth. It is the commonest congenital substrate for
    calcific stenosis and shifts presentation decades earlier.
    NOTCH1 loss-of-function links the two halves of the phenotype
    mechanistically: it produces
    the developmental leaflet anomaly, and because NOTCH1 signaling represses
    RUNX2, it also de-represses the osteogenic program that later calcifies the
    valve. The same lesion therefore both malforms the valve and removes a brake
    on its mineralization.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  genes:
  - preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  evidence:
  - reference: PMID:16025100
    reference_title: "Mutations in NOTCH1 cause aortic valve disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we show that mutations in the signalling and transcriptional regulator
      NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe
      valve calcification in non-syndromic autosomal-dominant human pedigrees.
    explanation: >-
      Establishes NOTCH1 as causal for both the developmental valve anomaly and
      the later severe calcification in human pedigrees.
  - reference: PMID:16025100
    reference_title: "Mutations in NOTCH1 cause aortic valve disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The incidence increases with age, and it is often associated with a
      bicuspid aortic valve present in 1-2% of the population.
    explanation: >-
      Supports the population frequency of the bicuspid substrate stated here.
  downstream:
  - target: Valve Endothelial Injury and Subendothelial Lipoprotein Retention
    causal_link_type: DIRECT
    description: >-
      Abnormal leaflet geometry concentrates mechanical and shear stress,
      accelerating endothelial injury.
  - target: Valve Interstitial Cell Osteogenic Transdifferentiation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      NOTCH1 haploinsufficiency de-represses RUNX2, lowering the threshold for
      osteogenic commitment independently of the flow abnormality.
- name: Valve Interstitial Cell Osteogenic Transdifferentiation
  biological_scale: CELLULAR
  description: >
    The pivot of the disease. Resident valve interstitial cells - fibroblast-like
    cells of the leaflet - switch to an osteoblast-like transcriptional program.
    Calcified human valves show increased expression of osteopontin, bone
    sialoprotein, osteocalcin, and the osteoblast master transcription factor
    RUNX2/Cbfa1 relative to normal valves. This is the step that separates
    calcific aortic valve disease from atherosclerosis: the tissue does not merely
    accumulate lipid and mineral debris, it executes a bone-formation program.
    NOTCH1 signaling normally represses RUNX2, which is why NOTCH1 loss both
    malforms and calcifies the valve.
  cell_types:
  - preferred_term: valve interstitial cell
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: osteoblast-like valve interstitial cell
    term:
      id: CL:0000062
      label: osteoblast
  biological_processes:
  - preferred_term: osteoblast differentiation
    term:
      id: GO:0001649
      label: osteoblast differentiation
    modifier: INCREASED
  genes:
  - preferred_term: RUNX2
    term:
      id: hgnc:10472
      label: RUNX2
  evidence:
  - reference: PMID:12719282
    reference_title: "Human aortic valve calcification is associated with an osteoblast phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Reverse transcriptase-polymerase chain reaction revealed increased mRNA
      levels of osteopontin, bone sialoprotein, osteocalcin, and Cbfa1 in the
      calcified valves.
    explanation: >-
      Provides the direct molecular evidence for an osteoblast transcriptional
      program in human calcified valves compared with normal valves.
  - reference: PMID:12719282
    reference_title: "Human aortic valve calcification is associated with an osteoblast phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings support the concept that aortic valve calcification is not a
      random degenerative process but an active regulated process associated with
      an osteoblast-like phenotype.
    explanation: >-
      States the reframing this node encodes - an actively regulated osteogenic
      process rather than passive degeneration.
  - reference: PMID:16025100
    reference_title: "Mutations in NOTCH1 cause aortic valve disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Notch1 repressed the activity of Runx2, a central transcriptional regulator
      of osteoblast cell fate.
    explanation: >-
      Supplies the molecular mechanism linking NOTCH1 loss to de-repression of
      the osteogenic program. Evidence source is IN_VITRO because the repression
      was demonstrated in cell-based transcriptional assays.
  downstream:
  - target: Valvular Calcification and Leaflet Mineralization
    causal_link_type: DIRECT
    description: >-
      The osteoblast-like program deposits mineral within the leaflet.
    hypothesis_groups:
    - osteogenic_autonomy
- name: Valvular Calcification and Leaflet Mineralization
  biological_scale: TISSUE
  description: >
    Calcium-phosphate mineral is laid down within the leaflet with the
    ultrastructure and composition of bone - hydroxyapatite, elemental calcium
    phosphate on energy-dispersive spectroscopy, mineralization borders on von
    Kossa staining. Mineralization stiffens the leaflet and further increases
    local mechanical stress, so the lesion is self-reinforcing. The extent of
    valvular calcification, not the patient's age, sex, or coronary or metabolic
    risk factors, is the independent predictor of clinical outcome in
    asymptomatic disease.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  biological_processes:
  - preferred_term: bone mineralization
    term:
      id: GO:0030282
      label: bone mineralization
    modifier: INCREASED
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: ABNORMAL
  evidence:
  - reference: PMID:12719282
    reference_title: "Human aortic valve calcification is associated with an osteoblast phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Special stains for hydroxyapatite and CaPO4 were positive in calcification
      margins. Electron microscopy identified mineralization, whereas
      energy-dispersive spectroscopy confirmed the presence of elemental CaPO4.
    explanation: >-
      Confirms that the deposited mineral is bone-type calcium phosphate rather
      than nonspecific debris.
  - reference: PMID:10965007
    reference_title: "Predictors of outcome in severe, asymptomatic aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      According to multivariate analysis, only the extent of aortic-valve
      calcification was an independent predictor of outcome, whereas age, sex,
      and the presence or absence of coronary artery disease, hypertension,
      diabetes, and hypercholesterolemia were not.
    explanation: >-
      Establishes leaflet calcification as the independent outcome determinant,
      and by exclusion shows that atherosclerotic risk factors are not.
  downstream:
  - target: Progressive Left Ventricular Outflow Obstruction
    causal_link_type: DIRECT
    description: >-
      Leaflet stiffening restricts systolic excursion and narrows the effective
      orifice area.
  - target: Valve Interstitial Cell Osteogenic Transdifferentiation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Mineral deposition raises local leaflet stiffness and mechanical strain,
      which further promotes osteogenic commitment - the feed-forward loop that
      makes established disease self-sustaining.
    hypothesis_groups:
    - osteogenic_autonomy
- name: Progressive Left Ventricular Outflow Obstruction
  biological_scale: TISSUE
  description: >
    The stiffened, mineralized valve narrows the outflow orifice, raising
    transvalvular velocity and the systolic pressure gradient the ventricle must
    generate. Progression is not uniform: the rate of increase in aortic-jet
    velocity varies widely between patients and is itself prognostic, separating
    those who will have events within a year or two from those who will not.
    This is why the disease is staged by progression rate as well as by severity.
  locations:
  - preferred_term: aortic valve
    term:
      id: UBERON:0002137
      label: aortic valve
  evidence:
  - reference: PMID:10965007
    reference_title: "Predictors of outcome in severe, asymptomatic aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The rate of progression of stenosis, as reflected by the aortic-jet
      velocity, was significantly higher in patients who had cardiac events
    explanation: >-
      Supports both progressive obstruction and the prognostic weight of its
      rate rather than its instantaneous severity.
  downstream:
  - target: Left Ventricular Pressure Overload and Concentric Hypertrophy
    causal_link_type: DIRECT
    description: >-
      A sustained systolic pressure gradient is the afterload stimulus for
      hypertrophic remodeling.
- name: Left Ventricular Pressure Overload and Concentric Hypertrophy
  biological_scale: TISSUE
  description: >
    The ventricle compensates for the fixed outflow obstruction by concentric
    hypertrophy, normalizing wall stress at the cost of a thicker, stiffer,
    less compliant chamber with a higher oxygen demand and a compressed
    subendocardial perfusion reserve. Hypertrophy is adaptive in the short term
    and the substrate for decompensation in the long term. Angina in aortic
    stenosis frequently occurs with unobstructed epicardial coronary arteries,
    reflecting this supply-demand mismatch rather than coexisting coronary
    disease.
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  cell_types:
  - preferred_term: cardiomyocyte
    term:
      id: CL:0000746
      label: cardiac muscle cell
  evidence:
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive myocardial fibrosis drives the transition from hypertrophy to
      heart failure in aortic stenosis.
    explanation: >-
      Places hypertrophy as the compensated stage preceding the fibrotic
      transition modeled downstream.
  downstream:
  - target: Myocardial Interstitial and Replacement Fibrosis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Sustained pressure overload and the resulting myocardial injury drive
      expansion of the extracellular compartment and focal replacement fibrosis.
- name: Myocardial Interstitial and Replacement Fibrosis
  biological_scale: TISSUE
  description: >
    Pressure-overloaded myocardium accumulates two distinguishable kinds of
    fibrosis. Diffuse interstitial fibrosis expands the myocardial extracellular
    volume and is at least partly reversible after the load is relieved.
    Replacement fibrosis - focal midwall scar following cardiomyocyte death,
    detected as late gadolinium enhancement - is not. Patients sort into a
    stepwise mortality gradient across normal myocardium, extracellular
    expansion, and replacement fibrosis, and in asymptomatic severe stenosis
    midwall fibrosis burden carries measurable additional risk. This is the
    node at which the disease stops being about the valve.
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  cell_types:
  - preferred_term: cardiac fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
    modifier: INCREASED
  evidence:
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diffuse fibrosis is associated with extracellular volume expansion that is
      detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects
      replacement fibrosis.
    explanation: >-
      Establishes the two-compartment distinction between diffuse interstitial
      and focal replacement fibrosis that this node asserts.
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      this categorization was of prognostic value with stepwise increases in
      unadjusted all-cause mortality
    explanation: >-
      Supports the stepwise mortality gradient across normal myocardium,
      extracellular expansion, and replacement fibrosis.
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      iECV demonstrated a good correlation with diffuse histological fibrosis on
      myocardial biopsies
    explanation: >-
      Validates the imaging surrogate against histology, which is what licenses
      treating extracellular volume as a fibrosis measurement rather than an
      imaging artifact.
  - reference: PMID:41984459
    reference_title: "Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      in asymptomatic patients with severe aortic stenosis, higher midwall
      fibrosis burden was associated with adverse outcomes.
    explanation: >-
      Extends the prognostic association into asymptomatic severe stenosis, where
      the valve gradient alone does not yet indicate intervention.
  downstream:
  - target: Left Ventricular Decompensation and Symptom Onset
    causal_link_type: DIRECT
    description: >-
      Fibrosis produces the diastolic and longitudinal systolic dysfunction that
      manifests as symptoms and drives events.
- name: Left Ventricular Decompensation and Symptom Onset
  biological_scale: ORGANISM
  description: >
    Diastolic dysfunction, longitudinal systolic dysfunction, and myocardial
    injury accumulate across the fibrosis stages until the compensated ventricle
    fails, producing exertional dyspnea, angina, syncope, and ultimately heart
    failure. Symptom onset is the classical trigger for intervention, and in
    prospectively followed asymptomatic patients almost all cardiac deaths were
    preceded by symptoms - which is what makes watchful waiting defensible, and
    also what makes the residual sudden-death risk so difficult to quantify.
  locations:
  - preferred_term: heart left ventricle
    term:
      id: UBERON:0002084
      label: heart left ventricle
  evidence:
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was evidence of increasing hypertrophy, myocardial injury, diastolic
      dysfunction, and longitudinal systolic dysfunction consistent with
      progressive left ventricular decompensation
    explanation: >-
      Documents the physiological components of decompensation tracking with
      fibrosis stage.
  - reference: PMID:10965007
    reference_title: "Predictors of outcome in severe, asymptomatic aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Five of the six deaths from cardiac disease were preceded by symptoms.
    explanation: >-
      Supports symptom onset as the near-universal antecedent of cardiac death in
      this cohort, the observation on which watchful waiting rests.
phenotypes:
- category: Cardiovascular
  name: Aortic Valve Stenosis
  description: >
    Obstruction of left ventricular outflow at the aortic valve, the defining
    lesion of the disease.
  phenotype_term:
    preferred_term: Aortic valve stenosis
    term:
      id: HP:0001650
      label: Aortic valve stenosis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:10965007
    reference_title: "Predictors of outcome in severe, asymptomatic aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we identified 128 consecutive patients with asymptomatic, severe aortic
      stenosis
    explanation: >-
      Identifies the defining lesion in a prospectively assembled clinical
      cohort.
- category: Cardiovascular
  name: Aortic Valve Calcification
  description: >
    Mineralization of the leaflets, the structural correlate of the osteogenic
    program and the strongest independent predictor of outcome in asymptomatic
    disease.
  phenotype_term:
    preferred_term: Aortic valve calcification
    term:
      id: HP:0004380
      label: Aortic valve calcification
  evidence:
  - reference: PMID:12719282
    reference_title: "Human aortic valve calcification is associated with an osteoblast phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Microradiography and micro-computerized tomography confirmed the presence
      of calcification in the valve.
    explanation: >-
      Directly documents leaflet calcification in surgically explanted human
      valves.
- category: Cardiovascular
  name: Bicuspid Aortic Valve
  description: >
    A two-leaflet aortic valve, present in 1-2% of the population and the
    commonest congenital substrate for early calcific stenosis.
  phenotype_term:
    preferred_term: Bicuspid aortic valve
    term:
      id: HP:0001647
      label: Bicuspid aortic valve
  evidence:
  - reference: PMID:16025100
    reference_title: "Mutations in NOTCH1 cause aortic valve disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      it is often associated with a bicuspid aortic valve present in 1-2% of the
      population.
    explanation: >-
      Supports the association of valve calcification with a bicuspid valve and
      its population frequency.
- category: Cardiovascular
  name: Left Ventricular Hypertrophy
  description: >
    Concentric hypertrophy of the left ventricle in response to the fixed
    outflow obstruction.
  phenotype_term:
    preferred_term: Left ventricular hypertrophy
    term:
      id: HP:0001712
      label: Left ventricular hypertrophy
  evidence:
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was evidence of increasing hypertrophy, myocardial injury, diastolic
      dysfunction, and longitudinal systolic dysfunction
    explanation: >-
      Documents hypertrophy in a phenotyped aortic stenosis cohort.
- category: Cardiovascular
  name: Myocardial Fibrosis
  description: >
    Diffuse interstitial and focal replacement fibrosis of the
    pressure-overloaded left ventricle; the burden of midwall fibrosis tracks
    mortality.
  phenotype_term:
    preferred_term: Myocardial fibrosis
    term:
      id: HP:0001685
      label: Myocardial fibrosis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      iECV demonstrated a good correlation with diffuse histological fibrosis on
      myocardial biopsies
    explanation: >-
      Anchors the fibrosis phenotype on histologically validated measurement.
- category: Cardiovascular
  name: Exertional Dyspnea
  description: >
    Breathlessness on exertion, typically the first symptom of decompensation and
    a conventional trigger for intervention.
  phenotype_term:
    preferred_term: Exertional dyspnea
    term:
      id: HP:0002875
      label: Exertional dyspnea
  evidence:
  - reference: PMID:24104373
    reference_title: "Asymptomatic aortic stenosis in the elderly: a clinical review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Angina, exertional syncope, and heart failure are key symptoms indicating a
      need for intervention.
    explanation: >-
      Names the symptom set that triggers intervention. Dyspnea is curated here
      as the presenting manifestation of the heart-failure component of that
      set.
- category: Cardiovascular
  name: Angina Pectoris
  description: >
    Exertional chest pain, frequently occurring without obstructive epicardial
    coronary disease because hypertrophy raises oxygen demand while compressing
    subendocardial perfusion reserve.
  phenotype_term:
    preferred_term: Angina pectoris
    term:
      id: HP:0001681
      label: Angina pectoris
  evidence:
  - reference: PMID:24104373
    reference_title: "Asymptomatic aortic stenosis in the elderly: a clinical review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Angina, exertional syncope, and heart failure are key symptoms indicating a
      need for intervention.
    explanation: >-
      Names angina among the symptoms whose appearance indicates a need for
      intervention.
  - reference: PMID:12732812
    reference_title: "Pathophysiology of valvular aortic stenosis in the elderly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eventually, symptoms of angina, non-Q wave myocardial infarction,
      exertional syncope, and heart failure occur.
    explanation: >-
      Independent source placing angina in the natural history of valvular
      aortic stenosis, alongside non-Q-wave infarction - which supports the
      supply-demand rather than epicardial-obstruction reading curated in the
      description.
- category: Cardiovascular
  name: Syncope
  description: >
    Exertional syncope, reflecting the inability to raise cardiac output across
    a fixed obstruction during peripheral vasodilation.
  phenotype_term:
    preferred_term: Syncope
    term:
      id: HP:0001279
      label: Syncope
  evidence:
  - reference: PMID:24104373
    reference_title: "Asymptomatic aortic stenosis in the elderly: a clinical review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Angina, exertional syncope, and heart failure are key symptoms indicating a
      need for intervention.
    explanation: >-
      Names syncope, and specifically its exertional character, among the
      intervention-triggering symptoms.
  - reference: PMID:12732812
    reference_title: "Pathophysiology of valvular aortic stenosis in the elderly."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eventually, symptoms of angina, non-Q wave myocardial infarction,
      exertional syncope, and heart failure occur.
    explanation: >-
      Independent source placing exertional syncope in the natural history of
      valvular aortic stenosis.
- category: Cardiovascular
  name: Congestive Heart Failure
  description: >
    The end stage of ventricular decompensation under chronic pressure overload.
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive myocardial fibrosis drives the transition from hypertrophy to
      heart failure in aortic stenosis.
    explanation: >-
      Supports heart failure as the terminal ventricular phenotype of the
      disease.
mechanistic_hypotheses:
- hypothesis_group_id: osteogenic_autonomy
  hypothesis_label: Autonomous osteogenic program
  status: CANONICAL
  description: >
    Once valve interstitial cells commit to an osteoblast-like program, leaflet
    mineralization becomes an actively regulated, self-reinforcing process that
    no longer depends on continued lipoprotein exposure. Deposited mineral raises
    local leaflet stiffness and strain, which further promotes osteogenic
    commitment. The prediction is that interventions upstream of the commitment
    step - lipid lowering in particular - will fail to modify progression of
    established disease, which is what randomized trials found.
  evidence:
  - reference: PMID:12719282
    reference_title: "Human aortic valve calcification is associated with an osteoblast phenotype."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      aortic valve calcification is not a random degenerative process but an
      active regulated process associated with an osteoblast-like phenotype.
    explanation: >-
      Supplies the core claim of an actively regulated osteogenic program in
      human calcified valves.
- hypothesis_group_id: lipid_driven_progression
  hypothesis_label: Lipid-driven atherosclerosis-like progression
  status: DEPRECATED
  description: >
    The historical model held that calcific aortic stenosis is an
    atherosclerosis-like, lipid-driven process throughout its course, predicting
    that LDL lowering would slow or halt valve progression. Two randomized trials
    tested this directly and refuted it for established disease. The model is
    retained here rather than deleted because its failure is what motivates the
    osteogenic-autonomy account, and because it remains partially correct about
    initiation - the LPA genetic evidence shows a lipoprotein species is causal
    at the start.
  evidence:
  - reference: PMID:15944423
    reference_title: "A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intensive lipid-lowering therapy does not halt the progression of calcific
      aortic stenosis or induce its regression.
    explanation: >-
      Directly refutes the prediction that lipid lowering modifies progression of
      established calcific aortic stenosis.
  - reference: PMID:18765433
    reference_title: "Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Simvastatin and ezetimibe did not reduce the composite outcome of combined
      aortic-valve events and ischemic events in patients with aortic stenosis.
    explanation: >-
      A second randomized trial refuting a lipid-lowering effect on aortic valve
      events.
- hypothesis_group_id: lipoprotein_a_specific_pathway
  hypothesis_label: Lipoprotein(a)-specific causal pathway
  status: EMERGING
  description: >
    Lp(a), rather than LDL cholesterol generally, may be the lipoprotein species
    that matters for the valve - plausibly through the oxidized phospholipids it
    carries. This reconciles the causal genetic association at LPA with the
    failure of statin and ezetimibe therapy, neither of which meaningfully lowers
    Lp(a). The prediction is that selective Lp(a) lowering would slow valve
    disease where LDL lowering did not; this has not yet been tested against a
    valve endpoint, so the hypothesis is genuinely open rather than merely
    unfashionable.
  evidence:
  - reference: PMID:23388002
    reference_title: "Genetic associations with valvular calcification and aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide
      significance for the presence of aortic-valve calcification
    explanation: >-
      Supplies the genome-wide genetic anchor that singles out the Lp(a) locus
      among lipid loci.
  - reference: PMID:23388002
    reference_title: "Genetic associations with valvular calcification and aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Currently, there are no treatments that prevent or slow the progression of
      valve disease.
    explanation: >-
      Records the therapeutic vacuum this hypothesis proposes to fill, stated by
      the same authors who established the genetic association.
treatments:
- name: Surgical Aortic Valve Replacement
  description: >
    Open surgical excision of the diseased valve and implantation of a mechanical
    or bioprosthetic replacement. Relieves the outflow obstruction and permits
    regression of hypertrophy and of diffuse interstitial fibrosis, but does not
    reverse established replacement fibrosis.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: aortic valve replacement
    term:
      id: NCIT:C50815
      label: Aortic Valve Replacement
  target_mechanisms:
  - target: Progressive Left Ventricular Outflow Obstruction
    treatment_effect: INHIBITS
    description: >-
      Replacing the leaflets eliminates the fixed obstruction and the pressure
      gradient driving ventricular remodeling.
  evidence:
  - reference: PMID:10965007
    reference_title: "Predictors of outcome in severe, asymptomatic aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These patients should be considered for early valve replacement rather than
      have surgery delayed until symptoms develop.
    explanation: >-
      Supports valve replacement as the definitive intervention and identifies
      the high-risk subgroup in whom earlier operation was recommended.
- name: Transcatheter Aortic Valve Replacement
  description: >
    Catheter-delivered implantation of a bioprosthetic valve within the diseased
    native valve, avoiding sternotomy and cardiopulmonary bypass. Now used across
    the surgical risk spectrum.
  therapeutic_modality: DEVICE
  treatment_term:
    preferred_term: transcatheter aortic valve replacement
    term:
      id: NCIT:C158018
      label: Transcatheter Aortic Valve Replacement
  target_mechanisms:
  - target: Progressive Left Ventricular Outflow Obstruction
    treatment_effect: INHIBITS
    description: >-
      The implanted prosthesis displaces the calcified native leaflets and
      restores an unobstructed outflow orifice.
  evidence:
  - reference: PMID:41984459
    reference_title: "Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Early intervention with transcatheter or surgical aortic valve replacement.
    explanation: >-
      Identifies transcatheter replacement alongside surgery as the intervention
      randomized in contemporary trials.
- name: Lipid-Lowering Therapy
  description: >
    Statin and ezetimibe therapy, historically expected to slow valve progression
    on the atherosclerosis analogy. Randomized trials refute this for the valve.
    Recorded here because the negative result is mechanistically informative
    rather than merely absent: in SEAS the same intervention in the same patients
    reduced ischemic events while leaving valve events untouched, dissociating the
    arterial from the valvular disease.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Valve Endothelial Injury and Subendothelial Lipoprotein Retention
    treatment_effect: INHIBITS
    description: >-
      Intended to reduce the retainable apoB-lipoprotein pool at the initiating
      lesion. The intended effect on valve progression was not observed.
  evidence:
  - reference: PMID:15944423
    reference_title: "A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intensive lipid-lowering therapy does not halt the progression of calcific
      aortic stenosis or induce its regression.
    explanation: >-
      Refutes a disease-modifying effect of lipid lowering on the valve lesion.
  - reference: PMID:18765433
    reference_title: "Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Simvastatin and ezetimibe did not reduce the composite outcome of combined
      aortic-valve events and ischemic events in patients with aortic stenosis.
    explanation: >-
      Second randomized refutation, on the primary composite endpoint.
  - reference: PMID:18765433
    reference_title: "Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aortic-valve replacement was performed in 267 patients (28.3%) in the
      simvastatin-ezetimibe group and in 278 patients (29.9%) in the placebo
      group (hazard ratio, 1.00; 95%
    explanation: >-
      The valve-specific null quantified: a hazard ratio of exactly 1.00 for
      aortic-valve replacement.
  - reference: PMID:18765433
    reference_title: "Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Such therapy reduced the incidence of ischemic cardiovascular events but
      not events related to aortic-valve stenosis.
    explanation: >-
      The dissociation itself: the same drug in the same patients modified the
      arterial disease and not the valve disease. This supports the mechanistic
      separation of the two, not the treatment.
discussions:
- discussion_id: as_fibrosis_prognostic_vs_treatment_selection
  kind: CONTROVERSY
  attaches_to:
  - "pathophysiology#Myocardial Interstitial and Replacement Fibrosis"
  prompt: >
    Does myocardial fibrosis burden identify asymptomatic patients who benefit
    from early valve replacement, or is it only a marker of risk?
  rationale: >
    The two questions are routinely conflated. Fibrosis burden is robustly
    prognostic - it predicts death and unplanned hospitalization in asymptomatic
    severe stenosis, and it grades mortality stepwise in symptomatic cohorts. It
    does not follow that intervening earlier in high-fibrosis patients helps.
    EVOLVED tested exactly this and found no interaction between fibrosis burden
    and treatment effect for the primary endpoint, although the
    hospitalization component did favor early intervention in the high-fibrosis
    group. A prognostic marker becomes a treatment-selection marker only when an
    interaction is demonstrated, and that demonstration has not been made.
  evidence:
  - reference: PMID:41984459
    reference_title: "Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was no demonstrable heterogeneity by the degree of midwall fibrosis
      for the treatment effects of early surgical or transcatheter aortic valve
      replacement compared to clinical surveillance.
    explanation: >-
      Directly refutes the treatment-selection interpretation of fibrosis burden
      on the trial's primary analysis.
  - reference: PMID:41984459
    reference_title: "Myocardial Fibrosis and Early Intervention in Asymptomatic Patients With Severe Aortic Stenosis: Insights From the EVOLVED Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      unplanned aortic stenosis-related hospitalization in 4 (7%) and 13 (25%)
      patients respectively
    explanation: >-
      The component result that keeps the question open: hospitalizations
      differed substantially in the high-fibrosis group even though the primary
      endpoint showed no interaction.
- discussion_id: as_osteogenic_commitment_reversibility
  kind: KNOWLEDGE_GAP
  attaches_to:
  - "pathophysiology#Valve Interstitial Cell Osteogenic Transdifferentiation"
  prompt: >
    Is the osteogenic commitment of valve interstitial cells reversible in vivo,
    and if so before what point?
  rationale: >
    The whole therapeutic logic of this disease turns on this question. If
    commitment is a switch, the only useful window for medical therapy is before
    it is thrown, and every trial that enrolled established stenosis was
    destined to be negative for reasons unrelated to the drug. If it is a
    gradient sustained by ongoing signaling, established disease remains
    addressable. No human study has tested reversal of the osteogenic program,
    and the negative lipid-lowering trials cannot distinguish the two
    possibilities because they did not target the program itself.
  proposed_experiments:
  - experiment_id: exp_as_osteogenic_activity_reversal
    name: Serial molecular imaging of valvular osteogenic activity during and after targeted intervention
    description: >-
      Track valvular osteogenic activity by serial molecular imaging in patients
      receiving, then withdrawing, a targeted anti-osteogenic intervention. If
      activity falls with treatment and returns only slowly, commitment is
      signal-dependent and established disease is addressable; if activity is
      unchanged throughout, commitment is autonomous.
  - experiment_id: exp_as_lpa_lowering_valve_endpoint
    name: Randomized selective Lp(a) lowering with a valve-calcification endpoint in early disease
    description: >-
      Randomize patients with early calcific aortic valve disease to selective
      Lp(a) lowering versus placebo with progression of valve calcification as
      the primary endpoint. Intervening upstream of osteogenic commitment
      separates the initiation hypothesis from the autonomy hypothesis in a way
      the completed statin trials could not, because those enrolled established
      stenosis.
- discussion_id: as_valve_interstitial_cell_ontology_gap
  kind: OPEN_QUESTION
  attaches_to:
  - "pathophysiology#Valve Interstitial Cell Osteogenic Transdifferentiation"
  prompt: >
    Should the valve interstitial cell have its own Cell Ontology term?
  rationale: >
    The valve interstitial cell is the central effector cell of the commonest
    valve disease in the developed world, has a distinctive
    quiescent-to-activated-to-osteogenic phenotypic repertoire, and is not
    adequately
    represented by CL:0000057 (fibroblast), which is what this entry uses. The
    osteoblast-like state is likewise curated here as CL:0000062 (osteoblast),
    which asserts more lineage identity than the literature supports - the
    sources describe an acquired phenotype, not a lineage conversion. Both
    bindings are approximations recorded openly rather than silently.
inheritance:
- name: Autosomal dominant NOTCH1-related aortic valve disease
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >
    Scoped deliberately to the NOTCH1 arm. Calcific aortic valve disease as a
    whole is an acquired, non-Mendelian condition of ageing, and no inheritance
    mode applies to it. But NOTCH1 loss of function segregates in
    autosomal-dominant pedigrees producing developmental leaflet anomalies with
    severe calcification, so that specific route into the disease does have a
    Mendelian mode. Recording it without this scoping would misdescribe the
    disease; omitting it entirely would lose the only inherited form.
  evidence:
  - reference: PMID:16025100
    reference_title: "Mutations in NOTCH1 cause aortic valve disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we show that mutations in the signalling and transcriptional regulator
      NOTCH1 cause a spectrum of developmental aortic valve anomalies and severe
      valve calcification in non-syndromic autosomal-dominant human pedigrees.
    explanation: >-
      States the autosomal-dominant, non-syndromic pedigree transmission that
      this block records, and confines it to the NOTCH1 arm.
diagnosis:
- name: Transthoracic Echocardiography
  description: >
    The diagnostic and staging modality. Echocardiography establishes leaflet
    calcification and restriction and quantifies severity by transvalvular peak
    velocity, mean gradient, and effective orifice area. It is also what defines
    disease progression in this entry, since the prognostic rate-of-change data
    are expressed as change in aortic-jet velocity per year.
  diagnosis_term:
    preferred_term: echocardiography
    term:
      id: NCIT:C16525
      label: Echocardiography Test
  evidence:
  - reference: PMID:10965007
    reference_title: "Predictors of outcome in severe, asymptomatic aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The rate of progression of stenosis, as reflected by the aortic-jet
      velocity, was significantly higher in patients who had cardiac events
    explanation: >-
      Documents the echocardiographic measurement (aortic-jet velocity) used to
      stage severity and track progression, and its prognostic weight.
- name: Exercise Stress Testing
  description: >
    Used to unmask symptoms in patients who report none, which matters because
    the whole management algorithm pivots on symptom status and patients
    routinely under-report by limiting their own activity. In the EARLY TAVR
    screening cohort, standardized treadmill testing of apparently asymptomatic
    patients with severe stenosis was positive in 15.2% - meaning roughly one in
    seven "asymptomatic" patients was not. It is safe in this population and
    nonetheless infrequently used.
  diagnosis_term:
    preferred_term: exercise cardiac stress test
    term:
      id: NCIT:C168192
      label: Exercise Cardiac Stress Test
  evidence:
  - reference: PMID:42485012
    reference_title: "Treadmill Stress Test in Patients With Asymptomatic Severe Aortic Stenosis: A Prespecified Registry-Based Follow-Up of the EARLY TAVR Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In patients with asymptomatic severe aortic stenosis (AS), exercise stress
      testing is recommended to unmask symptoms and guide the timing of
      intervention, yet it is infrequently used in clinical practice.
    explanation: >-
      States both the indication and the practice gap this entry records.
  - reference: PMID:42485012
    reference_title: "Treadmill Stress Test in Patients With Asymptomatic Severe Aortic Stenosis: A Prespecified Registry-Based Follow-Up of the EARLY TAVR Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of these, 816 (84.8%) had a normal TST result and 146 (15.2%) had a
      positive TST result.
    explanation: >-
      Quantifies how often apparently asymptomatic severe stenosis is unmasked
      by testing, which is what makes symptom status a measured rather than a
      reported variable.
  - reference: PMID:42485012
    reference_title: "Treadmill Stress Test in Patients With Asymptomatic Severe Aortic Stenosis: A Prespecified Registry-Based Follow-Up of the EARLY TAVR Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TST was found to be safe, with no reported deaths, syncope, or
      cardioversions.
    explanation: >-
      Addresses the historical safety concern about exercising patients with
      severe outflow obstruction.
- name: Cardiac Magnetic Resonance with Late Gadolinium Enhancement
  description: >
    Not needed to diagnose the valve lesion, but the only way to see the
    ventricular disease that determines survival. T1 mapping quantifies
    extracellular volume expansion (diffuse interstitial fibrosis) and late
    gadolinium enhancement detects focal replacement fibrosis; the two together
    stratify mortality stepwise, and midwall fibrosis burden is prognostic even
    in patients whose valve does not yet meet intervention criteria.
  diagnosis_term:
    preferred_term: cardiac magnetic resonance imaging
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  evidence:
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diffuse fibrosis is associated with extracellular volume expansion that is
      detectable by T1 mapping, whereas late gadolinium enhancement (LGE) detects
      replacement fibrosis.
    explanation: >-
      Establishes the two cardiac magnetic resonance measurements and what each
      detects.
  - reference: PMID:28017384
    reference_title: "Myocardial Fibrosis and Cardiac Decompensation in Aortic Stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CMR detects ventricular decompensation in aortic stenosis through the
      identification of myocardial extracellular expansion and replacement
      fibrosis.
    explanation: >-
      States the diagnostic claim: cardiac magnetic resonance is how ventricular
      decompensation is detected in this disease.
prevalence:
- population: Worldwide (Global Burden of Disease estimates)
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 138.0
  rate_low: 120.0
  rate_high: 158.0
  notes: >-
    9.6-12.6 million people worldwide with calcific aortic valve stenosis per
    Global Burden of Disease estimates. The rates per 100,000 are derived from
    those counts against a world population of roughly 8 billion and are
    therefore approximate; the count, not the rate, is what the source states.
  evidence:
  - reference: PMID:42177117
    reference_title: "The global burden of calcified aortic valve stenosis: epidemiology, risk factors, disparities, and future perspectives - a narrative review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The worldwide prevalence of CAVS is rising, affecting a 9.6 to 12.6 million
      people according to Global Disease Burden estimates
    explanation: >-
      Supplies the worldwide case count. Evidence source is OTHER because this is
      a narrative review of Global Burden of Disease estimates.
epidemiology:
- name: Global mortality burden
  description: >
    Calcific aortic valve stenosis contributes over 100,000 deaths worldwide each
    year, and the source attaches that burden specifically to the
    post-symptomatic phase - which is the entry's organising point restated
    epidemiologically.
  evidence:
  - reference: PMID:42177117
    reference_title: "The global burden of calcified aortic valve stenosis: epidemiology, risk factors, disparities, and future perspectives - a narrative review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Once symptoms emerge, CAVS is associated with high morbidity and mortality,
      contributing to over 100,000 deaths globally each year.
    explanation: >-
      Quantifies annual mortality and ties it to symptom emergence rather than to
      the presence of the valve lesion. Evidence source is OTHER because this is
      a narrative review.
- name: Rising global burden
  description: >
    Prevalence and incidence rose globally between 1990 and 2021, with the
    highest burdens in Western Europe and North America; ageing and population
    growth are the principal drivers.
  evidence:
  - reference: PMID:42129826
    reference_title: "Global, regional, and national burden of non-rheumatic calcific aortic valve disease from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021 and Mendelian randomization analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prevalence and incidence of NRCAVD increased globally between 1990 and
      2021, with higher burdens in Western Europe and North America.
    explanation: >-
      Documents the direction and geography of the trend from Global Burden of
      Disease data.
  - reference: PMID:42129826
    reference_title: "Global, regional, and national burden of non-rheumatic calcific aortic valve disease from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021 and Mendelian randomization analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aging and population growth drove the increase in DALYs, while body mass
      index was identified as a causal risk factor.
    explanation: >-
      Attributes the rising burden to demography and identifies body mass index
      as causal by Mendelian randomization.
- name: Event-free survival in asymptomatic severe aortic stenosis
  description: >
    Event-free survival in prospectively followed asymptomatic severe stenosis
    falls steeply, and the extent of valvular calcification stratifies it
    sharply.
  evidence:
  - reference: PMID:10965007
    reference_title: "Predictors of outcome in severe, asymptomatic aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Event-free survival for patients with no or mild valvular calcification was
      92+/-5 percent at one year
    explanation: >-
      Quantifies outcome in the low-calcification stratum of a prospective
      asymptomatic cohort.
genetic:
- name: LPA
  gene_term:
    preferred_term: LPA
    term:
      id: hgnc:6667
      label: LPA
  relationship_type: SUSCEPTIBILITY
  notes: >
    Common variation at the LPA locus, acting through circulating lipoprotein(a)
    concentration, is associated with aortic valve calcification and with
    incident clinical aortic stenosis across multiple ancestries.
  evidence:
  - reference: PMID:23388002
    reference_title: "Genetic associations with valvular calcification and aortic stenosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      One SNP in the lipoprotein(a) (LPA) locus (rs10455872) reached genomewide
      significance for the presence of aortic-valve calcification
    explanation: >-
      Genome-wide significant association of the LPA locus with aortic valve
      calcification.
- name: NOTCH1
  gene_term:
    preferred_term: NOTCH1
    term:
      id: hgnc:7881
      label: NOTCH1
  relationship_type: CAUSATIVE
  notes: >
    Loss-of-function mutations in NOTCH1 cause autosomal-dominant aortic valve
    disease combining developmental leaflet anomalies with severe calcification,
    mechanistically through de-repression of RUNX2.
  evidence:
  - reference: PMID:16025100
    reference_title: "Mutations in NOTCH1 cause aortic valve disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      mutations in the signalling and transcriptional regulator NOTCH1 cause a
      spectrum of developmental aortic valve anomalies and severe valve
      calcification in non-syndromic autosomal-dominant human pedigrees.
    explanation: >-
      Establishes NOTCH1 as a causal gene for human aortic valve disease.
📚

References & Deep Research

Deep Research

1
Claude Code ▸
Aortic Valve Stenosis: Comprehensive Disease Characteristics Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 44 citations 2026-08-10T14:13:17.393740

Aortic Valve Stenosis: Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Aortic valve stenosis (AS) is the narrowing of the aortic valve orifice that obstructs left ventricular outflow during systole. In adults in industrialized nations it is overwhelmingly an acquired, degenerative/calcific disease — often termed calcific aortic valve disease (CAVD) or calcific aortic valve stenosis (CAVS) — arising from an active, cell-mediated process of lipid deposition, chronic inflammation, fibrosis, and dystrophic calcification of the valve leaflets that is mechanistically distinct from, but shares risk factors with, atherosclerosis (PMID:31912380; PMID:32160774). It is the most common valvular heart disease in high-income countries and the most frequent indication for valve intervention in the elderly. Globally, however, rheumatic heart disease remains an important cause of aortic (and mitral) valve stenosis in low- and middle-income countries, and congenital bicuspid aortic valve (BAV) is the leading cause of AS presenting before age 65.

Key identifiers (verify exact codes at time of KB curation via OAK/authoritative sources before use): - ICD-10-CM: I35.0 (Nonrheumatic aortic (valve) stenosis); I06.0/I06.2 (Rheumatic aortic stenosis, with/without insufficiency); Q23.0 (Congenital stenosis of aortic valve) - ICD-11: BC71.0 (aortic valve stenosis, non-rheumatic) / BC63 rheumatic aortic valve diseases (foundation-layer codes; confirm exact ICD-11 MMS entry) - MeSH: D001024 (Aortic Valve Stenosis); D001022 (Aortic Valve Insufficiency, related) - OMIM: 109730 (Aortic Valve Disease 1; AOVD1 — NOTCH1-related congenital/BAV form); related syndromic entries include 185500 (Williams-Beuren syndrome, associated with supravalvular AS via ELN) and 300363 (Filamin A-related valvulopathy) - Orphanet: rare/syndromic subtypes are separately coded (e.g., isolated supravalvular aortic stenosis, Williams syndrome); degenerative calcific AS in the elderly is a common, non-rare disease and is not itself an Orphanet entry - MONDO: search "aortic valve stenosis" for the current MONDO ID; congenital and syndromic subtypes are separately coded (e.g., NOTCH1-related bicuspid aortic valve) - HPO: phenotype term "Aortic valve stenosis" (confirm exact HP ID via OAK) and "Bicuspid aortic valve" (HP:0004936, confirm)

Common synonyms/alternative names: Calcific aortic stenosis; senile/degenerative aortic stenosis; calcific aortic valve disease (CAVD); aortic sclerosis (the earliest, hemodynamically insignificant stage); valvular aortic stenosis; rheumatic aortic stenosis (etiology-specific); congenital aortic stenosis; bicuspid aortic valve stenosis; aortic valve calcification (AVC, when referring to the imaging/pathologic substrate rather than the hemodynamic lesion).

Data provenance for this report: Findings below are drawn from aggregated disease-level literature (systematic reviews, GWAS meta-analyses, randomized trials, registries such as PARTNER and the Global Burden of Disease study) rather than individual patient-level EHR data, consistent with standard knowledge-base curation sourcing.

2. Etiology

2a. Disease Causal Factors

Three broad etiologic categories converge on the same end-organ lesion (a stenotic, often calcified, aortic valve):

  1. Degenerative/calcific (most common in adults >65): an active biological process — not passive "wear and tear" — involving endothelial injury, lipoprotein infiltration (notably Lp(a) and oxidized LDL), macrophage/T-cell-driven chronic inflammation, valve interstitial cell (VIC) osteoblastic transdifferentiation, and progressive nodular calcification, closely paralleling early atherogenesis but diverging mechanistically in later stages (PMID:31912380; PMID:32160774).
  2. Congenital (bicuspid or, rarely, unicuspid/quadricuspid) valve: an abnormal two- (or one-) cusp valve morphology arising from developmental defects in endocardial cushion/valvulogenesis (notably via NOTCH1 signaling), which is hemodynamically stressed from birth and undergoes accelerated calcific degeneration, typically presenting 1–2 decades earlier than tricuspid degenerative AS.
  3. Rheumatic: post-infectious autoimmune valvulitis following group A Streptococcus pharyngitis (acute rheumatic fever), causing commissural fusion, leaflet fibrosis/retraction and, over years to decades, stenosis — almost always accompanied by mitral valve involvement and typically with mixed stenosis/regurgitation.

Less common causes: radiation-induced valvulopathy (mediastinal radiotherapy, e.g., for Hodgkin lymphoma or breast cancer, years after exposure), chronic kidney disease/dialysis-associated valvular calcification, familial hypercholesterolemia (homozygous, causing severe premature supra/valvular aortic disease), and inborn errors such as Fabry disease (glycosphingolipid deposition in valve tissue).

2b. Risk Factors

Genetic risk factors: - LPA locus / elevated lipoprotein(a) [Lp(a)] — the single strongest and most replicated genetic risk factor. GWAS identified rs10455872 and rs3798220 at the LPA locus, and Kringle IV type-2 copy-number variation, as determinants of plasma Lp(a) and of aortic valve calcium/AS risk (PMID cluster reviewed in PMC6787733, PMC9182826). A large Danish cohort/Mendelian-randomization study found a 10-fold increase in Lp(a) associated with an age/sex-adjusted hazard ratio of ~1.4 for AS, with an instrumental-variable (causal) estimate of ~1.6 — Mendelian randomization supports a causal role, not mere association (JACC 2013, PMID:24291273/doi 10.1016/j.jacc.2013.09.038). - PALMD (1p21) and TEX41 (2q22) loci — identified in the first large AS GWAS (Icelandic discovery cohort, 2,457 cases/349,342 controls, replicated in ~4,850 cases); rs7543130 (PALMD) OR≈1.20, P=1.2×10⁻²²; rs1830321 (TEX41) OR≈1.15, P=1.8×10⁻¹³. Both loci also associate with bicuspid aortic valve; TEX41 additionally associates with coronary artery disease (Nature Communications 2018, PMID:29511194). - NOTCH1 (9q34.3) — the gene with the strongest evidence for Mendelian/familial congenital aortic valve disease (OMIM 109730, Aortic Valve Disease 1/AOVD1, autosomal dominant). NOTCH1 loss-of-function mutations were first described by Garg et al. (2005) causing BAV with severe calcification, and account for an estimated 5–10% of non-syndromic BAV cases (PMC5573733; PMID:32720365). NOTCH1 haploinsufficiency both disrupts valvulogenesis and de-represses osteogenic gene programs (RUNX2, osteopontin) in adult VICs, linking developmental and degenerative calcification mechanisms; associations with osteoprotegerin/RANK/RANKL pathway dysregulation have also been reported (PMC5299165). - Multi-ancestry GWAS expansion — the Million Veteran Program multi-ancestry GWAS and subsequent integrative genomic analyses replicated ALPL, PALMD, TEX41, LPA, IL6, and FADS1, and identified additional novel loci, plus candidate causal genes implicated via tissue-specific regulatory analysis (Circulation 2023; Nature Communications 2024, doi:10.1038/s41467-024-46639-4). IL6, ALPL (tissue-nonspecific alkaline phosphatase, directly relevant to mineralization biochemistry), and NAV1 were highlighted as novel susceptibility genes in an earlier meta-analysis (bioRxiv 515494/subsequently published). - Other Mendelian/syndromic genetic causes: ELN (elastin) haploinsufficiency in Williams-Beuren syndrome (supravalvular AS, OMIM 185500); FLNA (filamin A) in X-linked myxomatous/dysplastic valvulopathy; homozygous familial hypercholesterolemia (LDLR, APOB, PCSK9) causing premature valvular and supravalvular calcific disease.

Environmental / clinical risk factors (largely overlapping with atherosclerotic risk factors, reflecting shared early pathobiology): - Advanced age (strongest non-genetic risk factor; prevalence rises steeply after age 65) - Male sex - Hypertension - Diabetes mellitus / metabolic syndrome - Smoking - Elevated LDL-cholesterol and elevated Lp(a) (also environmentally/dietarily modulated on top of genetic baseline) - Chronic kidney disease and CKD-mineral bone disorder (disordered calcium-phosphate handling promotes ectopic valvular/vascular calcification) - Prior mediastinal radiation therapy - Rheumatic fever history (for rheumatic AS specifically — itself driven by GAS pharyngitis exposure, crowding, and limited access to antibiotics/penicillin prophylaxis) - Bicuspid aortic valve (a structural risk factor rather than classic "environmental" one, but non-Mendelian in most sporadic cases)

Gene-environment interactions: Elevated Lp(a) and LDL act as substrates for the same oxidative and inflammatory processes that also respond to metabolic-syndrome/diabetogenic dietary exposures — demonstrated experimentally in LDLr⁻/⁻ApoB100/100 mice, where a diabetogenic/procalcific diet markedly accelerated valvular calcification beyond genotype alone (PMID:29539583). This models a genotype (LDL/Lp(a) handling) × environment (diet, metabolic syndrome) interaction analogous to atherosclerosis. CKD represents another gene-environment convergence point: uremic mineral dysregulation accelerates calcification in individuals already genetically predisposed via LPA/PALMD/ALPL risk alleles, though large-scale interaction studies specific to AS are less mature than for the general Lp(a)-CVD relationship.

2c. Protective Factors

No robust genetic protective variant is established (in contrast to LDL/PCSK9 loss-of-function protective alleles for coronary disease). Statins/aggressive LDL-lowering, despite strong observational and mechanistic rationale (parallel to atherosclerosis biology), failed to slow AS progression in randomized trials: - SALTIRE (atorvastatin vs placebo, n=155, up to 3 years): no reduction in aortic-jet velocity progression or valvular calcification. - SEAS (simvastatin/ezetimibe vs placebo; NEJM 2008, doi:10.1056/NEJMoa0804602): no significant effect on AS progression; possible signal of increased cancer incidence noted as a trial-specific finding. - ASTRONOMER (intensive rosuvastatin in mild-moderate AS; PMID:20080097): atorvastatin not associated with slowed hemodynamic progression. - Meta-analyses of ~2,344 patients across randomized placebo-controlled lipid-lowering trials concluded current data do not support statins as a disease-modifying therapy for established AS, in contrast to their clear benefit for atherosclerotic events — implying that once calcific remodeling is established, lipid lowering alone cannot reverse the fibro-calcific process, and/or that the intervention window (before overt stenosis) had already closed in enrolled cohorts.

This "statin paradox" is itself a key mechanistic finding: it argues that early lipid-driven initiation and later self-sustaining osteogenic/fibrotic progression are at least partly biologically distinct phases, motivating newer targeted approaches (Lp(a)-lowering agents such as pelacarsen and lepodisiran are in trials for atherosclerotic CVD, with dedicated Lp(a)-AS progression trials also underway; specific trial identifiers should be confirmed against ClinicalTrials.gov at curation time).

3. Phenotypes

Aortic stenosis is characteristically asymptomatic for years to decades (long latent/compensated phase) before symptoms emerge once the valve area falls below a critical threshold (~1 cm²) and left ventricular hypertrophy can no longer compensate.

Cardinal triad of symptoms (classically taught, sign of decompensation and adverse prognosis): - Exertional dyspnea/heart failure symptoms — most common; reflects diastolic dysfunction from concentric LV hypertrophy progressing to systolic dysfunction. HPO: consider "Dyspnea" (HP:0002094), "Exertional dyspnea" (verify HP ID), "Heart failure" (HP:0001635). - Angina — even without epicardial coronary disease, due to increased myocardial oxygen demand (hypertrophy) outstripping supply (reduced coronary flow reserve, shortened diastolic filling time). HPO: "Angina pectoris" (verify ID). - Syncope/presyncope, typically exertional — due to a fixed cardiac output unable to augment with exertion-induced peripheral vasodilation, and/or transient arrhythmia. HPO: "Syncope" (HP:0001279).

Additional clinical signs: - Harsh crescendo-decrescendo systolic ejection murmur, loudest at the right second intercostal space, radiating to the carotids - Diminished and delayed carotid upstroke (pulsus parvus et tardus) - Soft/absent S2 (calcified, immobile leaflets) - S4 gallop (atrial contraction against a stiff, hypertrophied ventricle) - Sustained/heaving apical impulse - Late complications: atrial fibrillation, heart failure with reduced or preserved EF, sudden cardiac death (particularly once symptomatic and untreated), acquired von Willebrand syndrome/Heyde syndrome (GI angiodysplasia bleeding due to shear-induced degradation of high-molecular-weight vWF multimers across the stenotic valve)

Laboratory abnormalities: elevated BNP/NT-proBNP (correlates with symptom onset and prognosis, used to trigger intervention in select asymptomatic patients per guidelines); acquired reduction of high-molecular-weight von Willebrand multimers (Heyde syndrome); no disease-specific routine chemistry abnormality otherwise.

Phenotype characteristics: - Age of onset: congenital (unicuspid, severe neonatal AS) presents in infancy; BAV-related AS typically presents in the 4th–6th decades; degenerative tricuspid calcific AS typically presents ≥65–70 years; rheumatic AS presents variably depending on access to acute rheumatic fever treatment/prophylaxis, often 3rd–5th decade in endemic regions. - Severity: graded echocardiographically as mild, moderate, severe (see Diagnostics), with "very severe" (peak velocity ≥5 m/s) increasingly recognized as an especially high-risk substage. - Progression: typically slow and progressive over years (mean jet-velocity progression roughly 0.1–0.3 m/s/year, mean gradient progression ~7 mmHg/year in some series), but rate is highly variable between individuals and can accelerate with worsening calcification burden, CKD, or in bicuspid valves. - Frequency of individual signs/symptoms among affected individuals: the systolic murmur is present in nearly all clinically significant cases; classic triad symptoms occur in a minority of the (large) asymptomatic population at any given time but portend a roughly 1–2%/year sudden-death risk once truly asymptomatic-but-severe, rising sharply once symptoms appear (~25% one-year mortality untreated, see Outcome/Prognosis).

Quality of life impact: Symptomatic AS substantially reduces functional capacity (NYHA class progression), exercise tolerance, and overall quality of life; validated general instruments (SF-36, EQ-5D) and disease-specific tools (Kansas City Cardiomyopathy Questionnaire, adapted for valve disease) show marked QoL improvement after successful valve replacement (TAVR or SAVR), a major endpoint in the PARTNER trial family.

Suggested HPO terms (verify exact IDs/labels via OAK before KB use): Aortic valve stenosis; Bicuspid aortic valve; Dyspnea; Exertional dyspnea; Syncope; Angina pectoris; Left ventricular hypertrophy; Heart failure; Atrial fibrillation; Sudden cardiac death; Systolic ejection murmur (or "Heart murmur").

4. Genetic/Molecular Information

Causal/high-risk genes (congenital/Mendelian forms): - NOTCH1 (HGNC:7881; OMIM 190198 gene / 109730 phenotype AOVD1) — autosomal dominant BAV and calcific AS; loss-of-function (haploinsufficient) variants; ~5–10% of non-syndromic familial/sporadic BAV (PMC5573733, PMID:32720365). - ELN (elastin) — Williams-Beuren syndrome (contiguous gene deletion, 7q11.23), causing supravalvular aortic stenosis as part of a multisystem elastin-arteriopathy syndrome (OMIM 185500). - FLNA (filamin A) — X-linked valvulo-septal defects with myxomatous, sometimes stenotic valve disease. - GATA4, GATA5, SMAD6, ROBO4, MAT2A, NOS3 and others — additional candidate/lower-penetrance genes reported in BAV cohorts via targeted and exome sequencing (systematic review: MDPI Genes 2024, doi:10.3390/genes15101309).

Common-variant / polygenic risk loci (degenerative CAVS): - LPA (rs10455872, rs3798220, KIV-2 copy number) — determines Lp(a) level; strongest and causally-supported (Mendelian randomization) common risk locus. - PALMD (1p21.2) and TEX41 (2q22.3) — first GWAS-identified non-LPA loci (PMID:29511194), both also linked to BAV. - ALPL (tissue-nonspecific alkaline phosphatase) — direct biochemical role in phosphate/mineralization biology. - IL6 — inflammatory pathway. - FADS1 — lipid/fatty-acid desaturation pathway. - NAV1 — novel candidate from meta-analysis. - Additional loci from the Million Veteran Program multi-ancestry GWAS and 2024 integrative genomics study, which nominated tissue-specific candidate causal genes via valve-tissue expression/regulatory data (Nat Commun 2024, doi:10.1038/s41467-024-46639-4).

Variant classification/frequency resources: ClinVar and ClinGen classify pathogenicity for NOTCH1/ELN/FLNA variants per ACMG/AMP criteria; gnomAD provides population allele frequencies for common-variant loci (LPA, PALMD, TEX41 alleles are common, MAF often >5–20% depending on ancestry, consistent with polygenic-risk rather than rare fully penetrant Mendelian variance for the bulk of adult degenerative AS).

Somatic vs. germline: AS-associated variants are germline; there is no established somatic-mutation driver analogous to clonal hematopoiesis in this disease (though CHIP/clonal hematopoiesis is an active research area for cardiovascular calcification broadly and may be relevant as an emerging modifier — flagged here as an area for further literature confirmation rather than an established causal link specific to AS).

Functional consequences: NOTCH1 variants are predominantly loss-of-function/haploinsufficient, disrupting Notch-mediated repression of osteogenic transcriptional programs in valve interstitial cells (de-repression of RUNX2/osteopontin-driven calcification) as well as impairing endocardial-cushion/valvulogenesis signaling during development — a dual developmental-and-degenerative mechanism (PMC5299165). LPA/Lp(a)-raising alleles act through a gain of circulating pro-atherogenic, pro-inflammatory, and oxidized-phospholipid-carrying lipoprotein particle rather than a coding loss/gain of a single protein's enzymatic function.

Epigenetic information: DNA methylation differences have been studied in Turner syndrome-associated BAV (PMC9194862) as a candidate modifier explaining incomplete penetrance/phenotypic variability of BAV in monosomy X; broader epigenomic studies of valve tissue (histone marks, chromatin accessibility) in sporadic CAVS are an active but less mature area relative to atherosclerosis epigenomics.

Chromosomal abnormalities: Turner syndrome (45,X and mosaic variants) carries markedly elevated BAV prevalence (14–34% across studies, vs. 0.5–2% general population) and consequent elevated AS risk, alongside coarctation of the aorta and aortopathy (meta-analysis, TechScience CHD journal; JACC 2008, PMID:18538181 area). 22q11.2 deletion syndrome and other conotruncal/left-heart developmental syndromes carry increased rates of left-sided obstructive lesions including AS, though BAV/AS is not the dominant cardiac phenotype in 22q11.2DS specifically.

5. Environmental Information

  • Environmental/toxic factors: No specific environmental toxin is established as a primary AS cause; chronic low-grade systemic inflammation and oxidative stress (shared with atherosclerosis) are the operative environmental-biological axis. Air-pollution/particulate-matter exposure has been studied as a contributor to vascular calcification broadly and is a plausible but not disease-specific established risk modifier for CAVS.
  • Radiation: Mediastinal/thoracic radiotherapy (Hodgkin lymphoma, breast, lung cancer treatment) is a well-established, dose- and latency-dependent cause of radiation-associated valvular heart disease, including accelerated aortic valve fibrosis and calcification appearing 10–20+ years post-exposure.
  • Lifestyle factors: Smoking, sedentary lifestyle contributing to metabolic syndrome/diabetes, and diets promoting dyslipidemia and hyperglycemia (mirroring the diabetogenic/procalcific diet used experimentally in LDLr⁻/⁻ApoB100/100 mice, PMID:29539583) are relevant modifiable contributors, primarily through acceleration of the shared lipid-inflammatory-calcific pathway rather than as independent disease initiators.
  • Infectious agents: Streptococcus pyogenes (Group A Streptococcus) is the infectious trigger for acute rheumatic fever, which via post-streptococcal autoimmune cross-reactivity (molecular mimicry between streptococcal M-protein epitopes and cardiac valve tissue) causes rheumatic valvulitis and, over years of recurrent/chronic disease, rheumatic aortic (and mitral) stenosis. This remains the dominant global cause of valvular AS in low-resource settings (RHD affects an estimated ~41 million people worldwide, causing ~1.4 million premature deaths annually, with the highest childhood cardiovascular DALY burden in ages 10–14; PMC7731852). Infective endocarditis can also cause secondary valve destruction/dysfunction but more typically causes regurgitation than pure stenosis.

6. Mechanism / Pathophysiology

Causal chain (degenerative calcific AS — the dominant adult mechanism)

  1. Initiating endothelial injury/dysfunction at sites of high mechanical shear/turbulent flow on the aortic (outflow) side of the leaflet — analogous to early atherogenesis (GO: response to fluid shear stress, GO:0034405).
  2. Lipoprotein infiltration and retention — LDL and especially Lp(a)-carried oxidized phospholipids (OxPL) accumulate in the subendothelial valve matrix; Lp(a) also delivers autotaxin, which generates lysophosphatidic acid, amplifying local inflammatory/pro-osteogenic signaling.
  3. Chronic inflammatory infiltration — macrophages, T lymphocytes, and mast cells infiltrate the leaflet; pro-inflammatory cytokines (IL-6, TNF-α, IL-1β) and complement activation sustain a self-perpetuating inflammatory microenvironment (GO: inflammatory response, GO:0006954).
  4. Valve interstitial cell (VIC) activation and osteoblastic transdifferentiation — resident VICs (normally quiescent fibroblast-like cells) activate into myofibroblasts and subsequently trans-differentiate into osteoblast-like cells expressing RUNX2, alkaline phosphatase (ALPL), osteopontin, and osteocalcin — a genuine ectopic bone-formation-like program (GO: osteoblast differentiation, GO:0001649; GO: bone mineralization, GO:0030282), counterbalanced physiologically by inhibitors such as osteoprotegerin (loss of which accelerates calcification in hypercholesterolemic mouse models, PMC3675204).
  5. Nodular calcification and matrix remodeling — deposition of calcium-phosphate (hydroxyapatite; CHEBI relevant to calcium phosphate mineral) at leaflet bases progressing toward the free edges, extracellular matrix degradation/remodeling by matrix metalloproteinases, and progressive leaflet stiffening.
  6. Neovascularization and intravalvular microhemorrhage contribute additional inflammatory and calcific stimulus in more advanced lesions.
  7. Mechanical outflow obstruction — leaflet stiffening and calcific bulk progressively reduce effective orifice area, imposing chronic pressure overload on the left ventricle.
  8. Compensatory concentric LV hypertrophy — normalizes wall stress initially (Laplace's law) but over time causes myocardial fibrosis, diastolic dysfunction, reduced coronary flow reserve, and eventually systolic dysfunction/heart failure once compensation fails.
  9. Clinical decompensation — symptom onset (angina, syncope, dyspnea) signals a marked increase in mortality risk absent intervention.

Upstream vs. downstream: Endothelial injury/lipid infiltration and the LPA/NOTCH1/PALMD genetic lesions sit upstream (initiating/predisposing); inflammatory amplification and VIC osteogenic transdifferentiation are the central, self-sustaining mid-pathway "engine" (explaining why upstream lipid-lowering with statins fails once this program is established); mechanical stenosis, LV hypertrophy, and heart failure are downstream consequences.

Cell types involved: valve interstitial cells (VICs; fibroblast-like, myofibroblast, osteoblast-like states), valve endothelial cells (VECs), infiltrating macrophages, T lymphocytes, mast cells, and — for the downstream cardiac remodeling arm — cardiomyocytes undergoing hypertrophy and interstitial cardiac fibroblasts. Suggested CL terms (verify exact IDs): "cardiac valve interstitial cell," "cardiac endothelial cell" (CL:1000487 candidate), "macrophage" (CL:0000235), "myofibroblast" (CL:0000186), "osteoblast" (CL:0000062, used here in an ectopic/trans-differentiated sense), "T cell" (CL:0000084), "cardiac muscle cell"/cardiomyocyte (CL:0000746).

Rheumatic mechanism (distinct pathway)

Group A streptococcal pharyngitis triggers an autoimmune cross-reactive (molecular mimicry) response targeting valvular endothelium and matrix proteins; recurrent/chronic inflammatory valvulitis produces commissural fusion, leaflet thickening/retraction and fibrosis, and secondary calcification — mechanistically an immune-mediated fibrotic process rather than the primarily lipid/osteogenic pathway of degenerative CAVS, though the two can converge on calcification as a final common pathway (dismech's granuloma_formation- and atherogenesis-adjacent, but non-identical, mechanism logic — a rheumatic AS entry would not conforms_to atherogenesis).

Molecular profiling / omics evidence

  • Transcriptomics: valve-tissue RNA-seq/microarray studies (deposited in GEO) have characterized differential expression of osteogenic (RUNX2, BMP2), inflammatory (IL6, TNF), and matrix-remodeling (MMPs) genes between calcified and normal leaflets, and underpin the tissue-specific regulatory analyses used in recent integrative GWAS follow-up (Nat Commun 2024).
  • Proteomics: valve and serum proteomic studies have identified osteopontin, osteocalcin, and complement components as enriched in calcified leaflets and, for some markers, in circulation.
  • Genomic structural features: copy-number variation at the LPA KIV-2 domain directly determines Lp(a) particle number/plasma level and thus genetic AS risk — a structural-genomic (not just SNP) contributor.
  • Single-cell/spatial approaches: emerging single-cell RNA-seq of human calcific valve tissue is beginning to resolve VIC subpopulation heterogeneity (quiescent vs. activated vs. osteogenic states) and immune cell diversity within lesions; this is a rapidly developing area as of 2025–2026 and specific dataset citations should be pulled from GEO/Human Cell Atlas at curation time.
  • Functional genomics: CRISPR/RNAi screens in valve interstitial cell culture systems have been used to interrogate osteogenic transdifferentiation regulators (e.g., RUNX2 pathway components), though this remains a smaller literature than for atherosclerosis-focused functional genomics (DepMap/BioGRID ORCS coverage of this specific phenotype should be checked directly if curating this level of detail).

7. Anatomical Structures Affected

Organ level: - Primary: the aortic valve (three leaflets/cusps in the normal tricuspid valve; two in BAV) and, immediately downstream, the left ventricle (concentric hypertrophy, later systolic dysfunction). - Secondary/complications: left atrium (pressure/volume overload contributing to atrial fibrillation), pulmonary vasculature and right heart (pulmonary hypertension, right heart failure in advanced disease), coronary circulation (reduced flow reserve despite often-normal epicardial arteries; concurrent atherosclerotic CAD is also common given shared risk factors), ascending aorta (post-stenotic dilation from turbulent jet, and — especially with BAV — an intrinsic aortopathy with aneurysm risk independent of hemodynamics), and (for BAV) association with aortic coarctation. - Body systems: primarily cardiovascular; secondarily hematologic (acquired von Willebrand syndrome/Heyde syndrome with GI bleeding), and — via reduced cardiac output — renal (cardiorenal interactions) and cerebrovascular (embolic stroke risk from calcific debris or associated atrial fibrillation).

Tissue and cell level: - Valve leaflet fibrosa, spongiosa, and ventricularis layers (trilaminar valve extracellular matrix architecture) undergo disorganization, fibrosis, and calcific nodule formation, predominantly on the fibrosa (aortic/outflow) side. - Cell populations: valve interstitial cells (activated/osteoblast-like), valve endothelial cells (dysfunctional), infiltrating macrophages/T cells/mast cells, and downstream cardiomyocyte hypertrophy plus interstitial myocardial fibroblast activation (fibrosis) in the left ventricle.

Subcellular level: mitochondrial oxidative stress in VICs contributes to osteogenic reprogramming; nuclear transcriptional reprogramming (RUNX2 activation) drives the osteoblast-like phenotype switch; extracellular matrix vesicles (a recognized nucleation site for hydroxyapatite deposition, paralleling bone/vascular calcification biology) are implicated in the mineralization step itself.

Localization/lateralization: Not applicable in the sense of unilateral/bilateral — the aortic valve is a single, midline structure — but calcification classically begins focally at leaflet bases near the commissures/hinge points and progresses toward the free margins, with the degree and distribution differing characteristically between tricuspid (more circumferential/central) and bicuspid (often raphe-centered, asymmetric) valve calcification, a distinction used clinically (e.g., in CT calcium scoring thresholds, which differ by sex and valve morphology).

Suggested UBERON terms: aortic valve (UBERON:0002137, verify); aortic valve leaflet (UBERON candidate, verify exact ID); left ventricle (UBERON:0002082); left ventricular myocardium; ascending aorta (UBERON:0001496, verify); left atrium (UBERON:0002079).

8. Temporal Development

Onset: - Congenital forms (unicuspid valve, severe neonatal critical AS) present at or shortly after birth, sometimes prenatally on fetal echocardiography. - BAV-associated AS most often becomes clinically significant in the 4th–6th decades of life, decades earlier than tricuspid degenerative AS, due to the additional mechanical stress of an abnormal two-cusp geometry. - Degenerative tricuspid calcific AS is an insidious, chronic process typically becoming hemodynamically severe after age 65–70, with prevalence rising steeply with each further decade of life. - Rheumatic AS onset is more variable, often presenting as clinically significant stenosis in the 3rd–5th decade in endemic, resource-limited regions, reflecting years of recurrent/subclinical rheumatic valvulitis following childhood acute rheumatic fever.

Progression: - Stages (echocardiographic, per current ACC/AHA staging framework): Stage A (at risk — e.g., BAV or early sclerosis without stenosis), Stage B (progressive, mild-moderate hemodynamic obstruction), Stage C (asymptomatic severe — C1 normal LV function, C2 LV dysfunction), Stage D (symptomatic severe — D1 high-gradient, D2 low-flow/low-gradient with reduced EF, D3 low-flow/low-gradient with preserved EF/paradoxical low-flow). - Progression rate: generally slow (years), quantifiable as annualized increase in peak velocity/mean gradient and decrease in valve area, but with substantial inter-individual variability; BAV, higher baseline calcium burden, CKD, and elevated Lp(a) are associated with faster progression. - Course pattern: typically unidirectional and progressive (no spontaneous regression of established calcific stenosis); asymptomatic patients can remain stable for years before relatively abrupt symptom onset once critical obstruction is reached, at which point the clinical trajectory changes sharply (a recognized "cliff-edge" prognostic transition, discussed further in Outcome/Prognosis). - Duration: chronic and, once truly severe and symptomatic, rapidly lethal without intervention (median survival on the order of ~2 years untreated after symptom onset, per classical natural-history literature, with more contemporary series estimating ~77% one-year survival in unoperated symptomatic patients, PMC3954323 area).

Patterns: - No spontaneous remission is described for calcific AS (unlike some inflammatory valvulopathies). - The key "critical period" from a management perspective is the transition from asymptomatic-severe to symptomatic disease — a major focus of intervention-timing guidelines and trials (e.g., debate over early intervention in asymptomatic severe AS, addressed by studies such as PMC8026050 and the JAMA Cardiology meta-analysis, doi:10.1001/jamacardio.2021.5528 area) — because outcomes worsen sharply once symptoms (or LV dysfunction/biomarker elevation) develop.

9. Inheritance and Population

Epidemiology: - Calcific/degenerative AS: prevalence rises steeply with age, generally cited in the range of a few percent of individuals over 65 and up to ~2–4% (severe AS specifically lower, on the order of 1–3%) in octogenarians in population-based echocardiographic screening cohorts (classic sources: Cardiovascular Health Study, Helsinki Aging Study, Framingham-related analyses — confirm exact contemporary percentages against a current source such as the JACC 2025 state-of-the-art review, doi:10.1016/j.jacc.2025.06.049, at curation time). - Global Burden of Disease-based estimates place non-rheumatic calcific aortic valve disease burden as rising substantially from 1990 to 2021 with further projected increases to 2050, tracking population aging (medRxiv 2025.02.05.25321722; JAHA 2024, doi:10.1161/JAHA.124.037991). - Aortic valve stenotic disease overall (all etiologies) is estimated to affect on the order of ~9 million people worldwide, with calcific disease dominant in high-sociodemographic-index (high-SDI) regions and rheumatic disease dominant in low-SDI regions (Nature Reviews Cardiology 2021, doi:10.1038/s41569-021-00570-z). - Bicuspid aortic valve: population prevalence ~0.9–1.36% by autopsy/screening series (up to ~4.6/1000 live births in a newborn screening cohort), making it the most common congenital heart defect.

Inheritance pattern (genetic forms): - NOTCH1-related AOVD1/BAV: autosomal dominant, with variable/incomplete penetrance and expressivity (some carriers have isolated BAV without stenosis; others develop severe calcific AS or thoracic aortic aneurysm). - Common-variant polygenic risk (LPA, PALMD, TEX41, ALPL, IL6, FADS1, etc.): complex/multifactorial inheritance — no single-gene Mendelian pattern; risk is cumulative and interacts with age and environmental exposures. - Williams-Beuren syndrome (ELN, supravalvular AS): autosomal dominant, typically due to a de novo 7q11.23 microdeletion (contiguous gene deletion syndrome), so usually not inherited from a parent but is transmissible at 50% risk if a parent is affected.

Penetrance/expressivity: Notably incomplete/variable for NOTCH1 and other BAV-associated genes — family members carrying the same variant may show isolated BAV, BAV with AS, BAV with aortopathy, or apparently normal valve morphology, motivating cascade echocardiographic screening in relatives of BAV probands.

Genetic anticipation: Not a recognized feature of AS (not a repeat-expansion disorder).

Founder effects / consanguinity: Not prominently described for common degenerative AS; may be locally relevant for specific rare Mendelian valvulopathy variants in genetically isolated populations, but this is not a well-characterized area in the mainstream AS literature.

Population demographics: - Sex ratio: BAV shows a strong male predominance (commonly cited 2:1 to 4:1 male:female across studies, with a newborn screening cohort reporting 4:1); however, sex differences in valve phenotype presentation exist — men with BAV more often present with aortic regurgitation, while women more often present with aortic stenosis (Circ Cardiovasc Imaging, PMID:28251911). Degenerative calcific AS in the elderly still shows a male predominance in incidence, though the gap narrows somewhat with the oldest age groups, and women may show relatively more fibrotic (versus purely calcific) valve remodeling patterns — an active area of sex-specific pathobiology research. - Turner syndrome (45,X): markedly elevated BAV prevalence (14–34% vs. 0.5–2% general population), making it an important syndromic subgroup for population-level AS risk. - Geographic distribution: rheumatic AS is concentrated in low- and middle-income countries (Sub-Saharan Africa, South Asia, Pacific Islander populations, Indigenous populations in some high-income countries) reflecting limited access to primary prevention (penicillin prophylaxis) and treatment of streptococcal pharyngitis/acute rheumatic fever; calcific AS predominates in aging high-income-country populations. - Age distribution: BAV-related AS peaks in middle age (40s–60s); degenerative tricuspid AS peaks in the elderly (>70–80); rheumatic AS varies by region but often presents younger than degenerative AS in endemic settings.

10. Diagnostics

Clinical/imaging tests: - Transthoracic echocardiography (TTE) is the primary diagnostic modality. Key parameters per current (2020 ACC/AHA and analogous ESC) guidelines: peak aortic jet velocity, mean transvalvular pressure gradient (MPG), and aortic valve area (AVA) by the continuity equation. Severe AS is defined by peak velocity ≥4 m/s, MPG ≥40 mmHg, and/or AVA ≤1.0 cm² (or indexed AVA ≤0.6 cm²/m²); "very severe" AS is increasingly recognized at peak velocity ≥5 m/s or ≥5.5 m/s, associated with markedly worse event-free survival (44%, 25%, 11%, 4% at 1–4 years in one cohort, AHA Circulation 2010-era study). - Four hemodynamic categories are defined when flow, gradient, and area are discordant: high-gradient severe AS; low-flow low-gradient AS with reduced LVEF (classical low-flow low-gradient); low-flow low-gradient AS with preserved LVEF (paradoxical low-flow, low-gradient); and normal-flow low-gradient AS with preserved LVEF — reflecting the complexity of grading in the presence of ventricular dysfunction or small ventricular cavities. - Dobutamine stress echocardiography helps distinguish truly severe AS with reduced contractile/flow reserve from pseudo-severe AS in low-flow, low-gradient, reduced-EF states. - Cardiac CT with aortic valve calcium (AVC) scoring (Agatston units) is a class-I-recommended adjunct in ACC/AHA/ESC guidelines specifically to resolve discordant/low-gradient grading, with established sex-specific severity thresholds (men and women have different calcium-score cutoffs for "severe" AS given differing valve calcification propensity). - Cardiac MRI for LV volumes/function, myocardial fibrosis (late gadolinium enhancement, T1 mapping) when echo is inconclusive or for research-grade fibrosis quantification. - Cardiac catheterization (invasive hemodynamic gradient measurement) reserved for cases of echo-catheterization discordance or when non-invasive data are inconclusive; coronary angiography (or coronary CTA) is routinely performed pre-intervention to assess concomitant CAD. - Biomarkers: BNP/NT-proBNP elevation supports symptomatic status/prognostic risk stratification and can help trigger earlier intervention in asymptomatic patients per guideline-endorsed thresholds. - Electrocardiography: may show LV hypertrophy pattern, left atrial abnormality, conduction disease (especially relevant peri-TAVR given proximity of the conduction system to the aortic annulus). - Histopathology (surgical/explanted valve specimens): shows fibrosis, dystrophic/nodular calcification predominantly on the aortic surface of the fibrosa layer, chronic inflammatory infiltrate, and neovascularization in advanced disease; rheumatic valves additionally show commissural fusion and characteristic fibrous thickening/retraction distinct from purely nodular calcific deposits.

Genetic testing: Not routine for typical sporadic degenerative or BAV-related AS, but recommended in the context of: familial clustering of BAV/thoracic aortic disease (first-degree relative screening echocardiography is guideline-recommended regardless of genetic testing; targeted gene panels including NOTCH1, ACTA2, TGFBR1/2, FBN1, SMAD3 etc. are used when a syndromic thoracic aortic aneurysm/BAV phenotype is suspected); suspected Williams-Beuren syndrome (chromosomal microarray/FISH for 7q11.23 deletion) in supravalvular AS; suspected homozygous familial hypercholesterolemia (LDLR/APOB/PCSK9 sequencing) in children/young adults with premature valvular/supravalvular calcific disease.

Clinical/differential diagnosis: Hypertrophic obstructive cardiomyopathy (dynamic subaortic/midcavitary obstruction, distinguished by echo features and provocative maneuvers), subvalvular/supravalvular aortic stenosis (fixed obstruction at a different anatomic level than the valve itself, important to distinguish since management differs — e.g., surgical membrane resection rather than valve replacement for discrete subvalvular membranes), aortic sclerosis (valve thickening/calcification without significant hemodynamic obstruction — the earliest point on the same disease continuum), and flow murmurs of other causes (anemia, hyperthyroidism, physiologic in young/athletic individuals) that can mimic the systolic ejection murmur without true stenosis.

Screening: No population-based screening program exists for degenerative AS given its age-related, largely non-preventable natural history; targeted echocardiographic screening is recommended for first-degree relatives of BAV/thoracic aortic aneurysm probands given the substantial heritable component, and for individuals with Turner syndrome given the markedly elevated BAV prevalence in that population.

11. Outcome/Prognosis

Survival/mortality: - Asymptomatic severe AS under watchful waiting: roughly 44% experience death or require valve replacement by 2 years in some cohorts; one comparative analysis found 1-year mortality of 5.2% (watchful waiting) vs. 4.7% (early surgery), and 2-year survival of 83.9% vs. 92.5% respectively, favoring earlier intervention in appropriately selected patients (Annals of Thoracic Surgery, PMID area referenced above). - "Very severe" AS (peak velocity ≥5.5 m/s): event-free survival of only 44%, 25%, 11%, and 4% at 1, 2, 3, and 4 years respectively if managed conservatively — among the strongest natural-history prognostic signals in cardiology (Circulation, PMID:20026779 area). - Symptomatic, unoperated severe AS: classically associated with a median survival around 2–3 years from symptom onset (angina ~5 years, syncope ~3 years, heart failure ~1–2 years, per the long-standing Ross-Braunwald natural-history framework); more recent series report ~77% one-year survival in unoperated symptomatic patients — still a markedly poor prognosis relative to treated disease. - Sudden cardiac death is a recognized risk in truly asymptomatic-but-severe AS (historically estimated around 1%/year), a key argument for evolving early-intervention strategies and biomarker/imaging-based risk stratification (JAMA Cardiology systematic review/meta-analysis on early intervention vs. watchful waiting in asymptomatic severe AS).

Post-intervention outcomes (TAVR/SAVR): - High surgical risk (PARTNER 1): 5-year mortality similar between TAVR (67.8%) and SAVR (62.4%), HR 1.04 (95% CI 0.86–1.24), demonstrating durable comparable outcomes in this population (Lancet 2015, PMID:25788234). - Intermediate risk (PARTNER 2): 24-month mortality 16.7% (TAVR) vs. 18.0% (SAVR) — non-inferior/comparable (NEJM 2016, PMID:27040324 area). - Low risk (PARTNER 3): TAVR superior to SAVR for the composite of death/stroke/rehospitalization at 1 year; by 7-year follow-up, TAVR and surgery show similar durability and valve function (NEJM 2025 7-year report, doi:10.1056/NEJMoa2509766) — a major, still-evolving evidence base extending TAVR's applicability across the full surgical-risk spectrum.

Morbidity/complications: heart failure, atrial fibrillation, stroke (both disease-related embolism and periprocedural), conduction system disease/need for permanent pacemaker (particularly post-TAVR, given proximity of the conduction system to the valve annulus), acquired von Willebrand syndrome with GI bleeding (Heyde syndrome, which characteristically resolves after valve replacement), and, for rheumatic disease, concomitant mitral valve disease compounding overall morbidity.

Quality of life: substantially improved after successful intervention (TAVR/SAVR), a primary endpoint across the PARTNER trial family and reflected in validated instruments (KCCQ, SF-36, EQ-5D).

Prognostic factors/biomarkers: symptom status (single strongest classical prognostic determinant), peak jet velocity/mean gradient severity ("very severe" category especially high-risk), LV ejection fraction and presence of low-flow states, degree of valve calcification (AVC score), elevated BNP/NT-proBNP, global longitudinal strain abnormalities (subclinical LV dysfunction), concomitant coronary artery disease, frailty and comorbidity burden (central to surgical/TAVR risk-scoring and candidacy decisions), and elevated Lp(a) (associated with both incident risk and, in some studies, faster hemodynamic progression).

12. Treatment

No effective pharmacotherapy modifies the natural history of the valvular lesion itself. Definitive treatment is mechanical relief of obstruction; medical therapy addresses risk-factor modification, symptom/heart-failure management, and comorbidities.

Pharmacotherapy (adjunctive/comorbidity management, not disease-modifying for the valve): - Standard heart failure and hypertension management (with caution regarding preload/afterload-sensitive agents in severe AS) once symptomatic or LV dysfunction present. - Statins/lipid-lowering: NOT disease-modifying for AS progression despite benefit for atherosclerotic risk reduction generally (SALTIRE, SEAS, ASTRONOMER — see Etiology/Protective Factors above); still indicated per standard cardiovascular risk criteria, just not "for" the valve disease itself. - Emerging investigational Lp(a)-lowering agents (e.g., pelacarsen, an antisense oligonucleotide, and lepodisiran, an siRNA) are in active clinical development primarily for atherosclerotic cardiovascular disease, with dedicated hypotheses/trials examining whether Lp(a) lowering can slow AS progression given the strong causal genetic evidence for Lp(a) in AS — specific trial identifiers, phase, and results should be confirmed against ClinicalTrials.gov/recent primary literature at curation time, as this is a fast-moving area. - Rheumatic AS: secondary antibiotic prophylaxis (penicillin) to prevent recurrent rheumatic fever/valvulitis is a cornerstone of preventing disease progression in that specific etiology (distinct from the calcific-disease pharmacology discussion above).

Surgical and interventional (definitive therapy): - Surgical aortic valve replacement (SAVR): long-standing gold-standard, using mechanical or bioprosthetic valves, with established durability data. - Transcatheter aortic valve replacement/implantation (TAVR/TAVI): catheter-based valve replacement, now guideline-supported across the low-to-high surgical risk spectrum based on the PARTNER trial program (PARTNER 1 high-risk PMID:25788234; PARTNER 2 intermediate-risk NEJM 2016; PARTNER 3 low-risk, 1-year superiority and 7-year comparable durability, NEJM 2019/2025) and parallel CoreValve/Evolut trial programs. TAVR has become the dominant intervention modality for symptomatic severe AS given its less invasive nature, with ongoing evidence generation on long-term (>10 year) valve durability, particularly relevant as TAVR is used in younger, lower-risk patients. - Balloon aortic valvuloplasty: a temporizing (not curative) procedure, used as a bridge to definitive TAVR/SAVR in hemodynamically unstable patients or those needing urgent noncardiac surgery, or in the pediatric/young congenital AS population where valve growth potential argues against prosthetic replacement. - Ross procedure (pulmonary autograft) — an option in select younger patients, particularly in congenital/pediatric AS, avoiding lifelong anticoagulation and allowing growth.

Rehabilitative/supportive care: cardiac rehabilitation post-intervention; standard heart-failure supportive management for those not undergoing intervention or awaiting it; endocarditis-prophylaxis counseling for prosthetic valve recipients per current guidelines.

Experimental/investigational: Lp(a)-lowering agents as above; osteoprotegerin/RANKL-pathway-targeted approaches remain preclinical (mouse model rationale from PMC3675204) rather than in clinical trials for AS specifically; anti-inflammatory strategies analogous to those tested in atherosclerosis (e.g., canakinumab-class IL-1β inhibition) are of mechanistic interest given the IL6 GWAS signal but are not established AS therapies.

Treatment outcomes: As detailed under Prognosis — TAVR and SAVR produce comparable survival across risk strata in randomized trials, with TAVR showing an early advantage in low-risk patients for the composite endpoint at 1 year and comparable long-term valve durability out to 7 years.

Personalized/precision approaches: risk-stratified selection between TAVR and SAVR based on surgical risk scores (STS-PROM, EuroSCORE II), frailty assessment, valve/annulus anatomy (including bicuspid-specific anatomic considerations that affect TAVR device selection and outcomes), and access-site/vascular anatomy; genotype-informed risk assessment (e.g., elevated Lp(a) or known familial NOTCH1 BAV) is increasingly used to guide surveillance intensity and cascade family screening rather than to select a specific drug therapy at present.

Suggested NCIT terms: Surgical Procedure (NCIT:C15329); Transcatheter Aortic Valve Replacement (confirm exact NCIT ID, candidate NCIT:C80324); Pharmacotherapy (NCIT:C15986); Organ/Valve Transplantation-adjacent procedure codes as applicable; Balloon Valvuloplasty (confirm NCIT ID); Cardiac Rehabilitation (NCIT candidate, confirm).

13. Prevention

  • Primary prevention: Modifiable-risk-factor control (blood pressure, LDL-cholesterol per general cardiovascular risk guidelines, smoking cessation, diabetes/metabolic-syndrome management) reduces atherosclerotic cardiovascular risk broadly but has not been shown to prevent the specific development of calcific AS, given the negative statin trials described above — this is an important, somewhat counterintuitive point distinguishing AS from coronary disease prevention. For rheumatic AS specifically, primary prevention of acute rheumatic fever via prompt antibiotic treatment of streptococcal pharyngitis is genuinely effective and central to reducing global RHD-attributable AS incidence, particularly in low-resource, high-incidence settings.
  • Secondary prevention: Secondary antibiotic (penicillin) prophylaxis after acute rheumatic fever prevents recurrent valvulitis and thus limits progression to (or worsening of) rheumatic aortic/mitral stenosis — a well-established, guideline-endorsed intervention. For calcific AS, "secondary prevention" in practice means surveillance echocardiography at guideline-recommended intervals (frequency scaled to severity stage) to detect progression to severe/symptomatic disease at the optimal point for intervention, since no medical therapy prevents progression once the process has begun.
  • Tertiary prevention: Timely valve replacement (TAVR/SAVR) prevents the downstream complications of untreated severe symptomatic AS (heart failure, sudden death); post-intervention care (endocarditis prophylaxis for prosthetic valves, anticoagulation management for mechanical valves, periodic prosthetic valve surveillance) prevents intervention-related complications.
  • Screening/early detection: targeted (not population-wide) echocardiographic screening of first-degree relatives of BAV/thoracic-aortopathy probands and of individuals with Turner syndrome, given markedly elevated baseline risk in these groups; risk stratification using AVC scoring and biomarkers (BNP/NT-proBNP) to identify asymptomatic patients who may benefit from earlier intervention.
  • Genetic counseling: relevant for families with NOTCH1-associated autosomal dominant BAV/AOVD1, Williams-Beuren syndrome (recurrence risk essentially that of a de novo microdeletion, low for future pregnancies unless germline mosaicism), and homozygous familial hypercholesterolemia (autosomal codominant, with defined recurrence risk counseling for LDLR/APOB/PCSK9 pathogenic variants).
  • Public health interventions: for rheumatic AS, public-health-level investment in access to primary care/antibiotics for streptococcal pharyngitis, improved living conditions (reducing overcrowding-driven GAS transmission), and RHD control programs (echocardiographic screening programs for latent RHD in endemic regions, WHO-endorsed) represent the most effective population-level prevention strategy for this etiology globally.
  • Prophylaxis: infective endocarditis antibiotic prophylaxis is recommended for patients with prosthetic aortic valves (and select other high-risk categories) undergoing specified dental/procedural exposures, per current AHA/ESC guidelines.

14. Other Species / Natural Disease

  • Taxonomy: naturally occurring aortic/subaortic valvular stenosis is well described in domestic dogs (NCBITaxon:9615, Canis lupus familiaris), particularly as subvalvular aortic stenosis (SAS), a congenital fixed left ventricular outflow tract obstruction with strong breed predisposition.
  • Breed: Newfoundlands, Golden Retrievers, Rottweilers, Boxers, and German Shepherd Dogs are classically over-represented for canine subvalvular/aortic stenosis (breed-specific Vertebrate Breed Ontology/VBO identifiers should be confirmed at curation time; this is a well-established heritable condition in Newfoundlands specifically, with published pedigree/heritability analyses).
  • Gene: the specific causal genetic variant(s) for canine SAS are less definitively characterized than the human NOTCH1/LPA loci, though it is recognized as heritable with a complex/polygenic inheritance pattern in most studied breeds; orthology to human developmental valve genes (e.g., NOTCH1 pathway members) is biologically plausible but not established as the confirmed canine mechanism in the literature reviewed here — flag for targeted OMIA/veterinary literature confirmation if curating this comparative angle in detail.
  • Natural disease and veterinary relevance: canine SAS is one of the most common congenital cardiac defects in dogs and a significant cause of exercise intolerance, syncope, and sudden cardiac death in affected large-breed dogs, giving it substantial veterinary clinical importance and making affected dogs a naturally-occurring (rather than experimentally induced) comparative model.
  • Comparative pathology: the fixed left ventricular outflow obstruction, compensatory LV hypertrophy, and risk of sudden death parallel human congenital/valvular AS pathophysiology, though the anatomic level (frequently subvalvular fibrous ridge/membrane in dogs) and degenerative-calcific biology differ from adult human calcific AS — better viewed as a comparative model for congenital/subvalvular obstruction than for the lipid-driven calcific pathway.
  • Transmission/zoonotic potential: not applicable — this is a non-infectious structural cardiac disease in the calcific/congenital forms; note that the infectious trigger for rheumatic AS (Group A Streptococcus) is itself a human-adapted pathogen without a natural zoonotic reservoir relevant to this disease pathway.

15. Model Organisms

Genetically engineered and diet-induced mouse models (the dominant experimental system for calcific AS mechanism research): - Ldlr⁻/⁻ mice: develop aortic/vascular calcification with a distribution paralleling human disease; used with micro-CT quantification as a model for aortic calcification generally (PMID:22051553). - Ldlr⁻/⁻ApoB100/100 mice: hypercholesterolemic model prone to aortic valve calcification and oxidative stress with functional valvular disease mimicking the clinical syndrome; a customized diabetogenic/procalcific diet further accelerates calcification, hyperglycemia, and obesity in this model, directly modeling gene(lipid handling)×diet(metabolic syndrome) interaction (PMID:29539583). - Notch1⁺/⁻ heterozygous mice (on high-cholesterol diet): an established small-animal model of calcific aortic valve disease reflecting the human NOTCH1-haploinsufficiency mechanism; used, for example, to test genetic ablation of serotonin receptor 2B (Htr2b), which improved aortic valve hemodynamics in this model (PMC7688160), illustrating the model's utility for testing candidate modifier genes/pathways. - Aged hypercholesterolemic mice (without additional genetic valve-specific lesions): develop calcific AS with aging plus hypercholesterolemic diet, supporting age as an independent, non-genetic experimental variable (PMID:17075015). - Hypercholesterolemic/hypertensive combined mouse models: develop a more fibrotic (versus purely calcific) valve stenosis phenotype, useful for modeling the fibrotic component of human CAVD and potentially for sex- or subtype-specific human disease correlates (PMC4767592). - Osteoprotegerin (Opg) pathway models: OPG administration/genetic manipulation in hypercholesterolemic mice modulates valve calcification and preserves valve function, supporting OPG/RANK/RANKL as a therapeutic target axis (PMC3675204).

Model characteristics: - Phenotype recapitulation: these models reproduce key histopathologic features (lipid deposition, macrophage infiltration, osteogenic marker expression, calcific nodule formation) and, in several models, measurable hemodynamic valve dysfunction (reduced valve area, increased velocity by echocardiography), giving reasonable face validity for the initiation/inflammatory/early-osteogenic phases of human disease. - Model limitations: mice do not naturally develop the degree of leaflet macro-calcification and hemodynamically severe stenosis seen in elderly humans without genetic/dietary manipulation and prolonged time courses; the mouse valve is anatomically smaller and structurally distinct; models largely capture the LDL/cholesterol-driven and Notch-pathway-driven arms but less fully recapitulate the Lp(a)-driven arm (mice do not naturally express an LPA-orthologous gene generating human-like Lp(a) particles, a recognized cross-species translational gap given how central Lp(a) is to human genetic risk — a candidate HUMAN_MODEL_MISMATCH-type caveat if this disease were curated into a mechanism module framework); rheumatic-etiology AS has no direct standard rodent model given its human-adapted streptococcal/autoimmune basis. - Research applications: these models are used to dissect the initiating lipid/inflammatory phase, test candidate therapeutic targets (OPG/RANKL, serotonin receptor 2B, and others) before human trials, and to generate mechanistic hypotheses for pathways (e.g., IL6, ALPL) subsequently supported by human GWAS. - Resources: Mouse Genome Informatics (MGI) for strain/allele records (e.g., Ldlr and Notch1 alleles), International Mouse Phenotyping Consortium (IMPC) for systematic knockout phenotyping data potentially relevant to candidate valve-calcification genes, and GEO for deposited transcriptomic datasets from these valve-calcification mouse models.

Summary for Knowledge-Base Curation

This disease is best modeled with at least two distinct etiologic pathophysiology chains given its heterogeneous causation: (1) a degenerative/calcific chain (endothelial injury → lipid/Lp(a) infiltration → chronic inflammation → VIC osteoblastic transdifferentiation → nodular calcification → mechanical obstruction → LV hypertrophy/heart failure), strongly analogous to — but mechanistically distinct from — the dismech atherogenesis module, and a plausible candidate for its own dedicated "calcific valvulopathy" mechanism module given its recurrence pattern (it would also be a strong candidate to conforms_to a future cardiomyopathy_maladaptive_remodeling node for the downstream LV-hypertrophy-to-heart-failure arm); and (2) a rheumatic/autoimmune chain (GAS pharyngitis → molecular mimicry autoimmune valvulitis → commissural fusion/fibrosis → stenosis), which is mechanistically distinct and should not be conflated with the calcific pathway in a single pathophysiology chain. Congenital/BAV forms sit partly upstream of the calcific chain (as an "at-risk" structural predisposition, Stage A in the ACC/AHA framework) rather than being a wholly separate mechanism. The strongest, most rigorously evidenced single risk factor for curation priority is the LPA/Lp(a) axis (Mendelian-randomization-supported causality); NOTCH1 is the best-evidenced Mendelian congenital driver; and the negative statin trial evidence (SALTIRE/SEAS/ASTRONOMER) is an important, well-documented "expected but disconfirmed" treatment hypothesis worth explicitly capturing as a mechanistic_hypotheses/discussion entry rather than omitting.

Sources